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 Cysteine cathepsins are an important class of enzymes that coordinate a variety of 
important cellular processes, and are implicated in various types of human diseases. Still 
however, many of their cellular function remain poorly understood. Chemical biology 
approaches employing small molecules can be utilized for this purpose. Unfortunately small 
molecule probes that are cell-permeable and non-peptidyl in nature are scarcely available.  
In this work, first a library of sulfonyloxiranes is synthesized. From this library, 2-(2-
ethylphenylsulfonyl)oxirane is identified as a selective inhibitor of cysteine cathepsins. Cell-
based study reveals that 2-(2-ethylphenylsulfonyl)oxirane is a cell-permeable, covalent, and 
irreversible inhibitor of cathepsin B with modest efficacy. 
 Next, a hybrid-design approach is undertaken to develop a highly potent and selective 
peptidyl vinylsulfonates inhibitor (KD-1) of human cathepsin L. Studies involving human breast 
carcinoma MDA-MB-231 cells establishes that this inhibitor can successfully block intracellular 
cathepsin L activity, and retards the cell-migratory potential of these highly metastatic cells. This 
work has been further extended to develop an activity-based probe (KDP-1) of cathepsin L by 
suitable modification of KD-1 inhibitory scaffold. KDP-1 has been found to be so far the most 
potent activity-based probe of cathepsin L. Cell-based studies are currently underway to 
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demonstrate the cellular efficacy of KDP-1. Further, KDP-1 is anticipated to find extensive 
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 Aspartate Protease 
 Metalloprotease 
 Serine Protease 
 Cysteine Protease 
Figure 1.1. Classification of Proteases. 
1.1 BACKGROUND 
Proteases are a class of enzymes that catalyze the hydrolysis of their protein substrates. 
They are found in almost all types of living organisms that include mammals, viruses, bacteria, 
protozoa, plants and fungi.
1
 Proteases have been categorized based on their active site catalytic 
residues that they use for catalysis.  There are four 
existing classes of proteases: aspartate protease, 
metalloprotease, serine protease and cysteine 
protease (Figure 1.1). The emergence of several 
newly discovered proteases necessitate further 
classification to differentiate proteases within their 
distinct catalytic category into evolutionary families 
and clans.
2
 MEROPS is an evolving database where emergence of newly discovered proteases is 
regularly indexed.
1, 3
 Cysteine proteases have been further categorized in three structurally 
distinct subclasses: the papain family, the caspase family, and the picornaviridae family.
4
 The 
papain family of enzymes represent majority of the cysteine proteases.
5
 Cysteine cathepsins 
belong to the papain family of enzyme. There are eleven members of cysteine cathepsins 
(cathepsin B, C/J/dipeptidyl peptidase I, F, H, L, K, O, S, W, V and Z/X/P) that are primarily 
housed in membrane-bound organelles called lysosomes. They have unique catalytic machinery 
and tissue specific expression pattern
6
 and they mediate many essential physiological processes.
6
 
Aberrant expressions of cysteine cathepsins have been associated with different types of 
diseases, such as bone loss, autoimmune disease, metabolic syndrome and metastatic cancer.
6
 
Thus, developing inhibitors of cysteine cathepsins have potential to (a) treat a wide range of 
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diseases, (b) assessing unknown functions of cysteine cathepsins in various cellular contexts. It is 
thus imperative to develop new classes of inhibitors to address the aforementioned issues. 
1.2 Regulation and Structure 
 Cysteine cathepsins are synthesized as preproenzymes which are composed of a signal 
peptide, a propeptide and a catalytic domain (Figure 1.2.A).
6
 Signal peptides are composed of 
10-20 amino acid residues, and are responsible for translocation into the endoplasmic reticulum 
during mRNA translation.
7
 Cleavage of signal peptide yields propeptide
8
 that plays important 
role in cathepsin biology.
9
 The role of propeptide segment is manyfold: (a) it assists in proper 
folding of enzyme,
7
 (b) it uses  very specific mannose-6-phosphate receptor (M6PR) pathway to 
direct localization to endosomal/lysosomal compartment,
7
 and (c) it acts as a high-affinity 
reversible inhibitor of cognate enzymes that prevents any aberrant zymogen activity.
10
 Cleavage 
of propeptide releases proteolytically active mature cathepsins which vary in length between 214 
amino acid residues to 260 amino acid residues.
6
 
Cysteine cathepsins are relatively small monomeric proteins with molecular weights in 
the range of 24–35 kDa.
11
 Cathepsin C is the only exception to this and is a tetramer with a 
molecular weight of 200 kDa.
11
 Determination of papain structure was the first structural 
elucidation of papain-like cysteine proteases. Except cathepsin O and W
7
 three dimensional 

















, and cathepsin C
20
). 
All cysteine cathepsins share the common fold of papain like structure. Cathepsin L has been 
chosen as a prototypical of cysteine cathepsin class of enzymes for structural elucidation (Figure 
1.2.B).
13
 Cathepsin L is a bilobal protein that consists of two structurally distinct domains; left 
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(L) domain and right (R) domain (Figure 1.2.B). The structure of the active cathepsin L 
resembles a closed book with the spine at the front
13
 where two domains form a V-shaped active 
site at the interface. Catalytic site of the enzyme lies within the active site that is composed of a 
Cys25 (from left domain) and His163 (from right domain). Together they form a thiolate-
imidazolium ion pair which imparts enhanced nucleophilicity to the cysteine residue.
21
 The 
nucleophilic thiolate residue in turn participates in cleavage of the scissile peptide bond. The left 
domain contains three α-helixes. Among these, central α-helix is longest in length and is 
composed of 30 amino acid residues.
6







Figure 1.2. [A] Representation of cathepsin L as a preproenzyme. [B] Fold of mature 
cathepsin L (PDB id: 1icf). The side chains of catalytic residues cysteine 25 (yellow) 
and histidine 163 (blue) are shown as ball and stick model. (Carson, 1997). [C] Fold 
of procathepsin L (PDB id: 1cjl). The mature enzyme part of cathepsin L is shown in  
cyan and the propeptide is shown in maroon. (Turk & Guncar, 2003) 
   







shape which includes a shorter α-helical motif.
13
 The propeptide binds to the active site cleft 





The proteolytic activities of mature cathepsins are also regulated by few physiological 
factors. For example, cysteine cathepsins are optimally active under acidic environment of 
lysosome. Most of them lose activity at neutral pH, except cathepsin S which is active even at 
slight alkaline pH.
23
 It should also be noted that active site cysteine is prone to oxidation. Thus 
endosome accumulates cysteine to retain the reducing environment with in the cell.
24
 Finally, 




1.3 Substrate Binding and Specificity 
 The seminal work by Berger and Schechter in 1967 was the first elucidation of substrate 
binding to the active site of cysteine protease.
26
 Their study examined the influence of substrate 
chain length on substrate kinetics. Based on their discovery they have developed a nomenclature 
in which individual enzyme pockets have been designated as ‘S’ and substituents approaching 
from the peptide substrate have been depicted as ‘P’ (Figure 1.3.A). Three decades later, Turk et 
al.
27
 revisited and redefined the substrate binding to the active site of papain like cysteine 
proteases (Figure 1.3.B).
13
 The active site is comprised of amino acid residues approaching from 
both the lobes.
11
 The L-lobe contributes two shorter loops (Gln19-Cys25, Arg59-Tyr67) 
connected by a disulfide bridge (Cys22-Cys63) thus making it an additional loop closure
6
. 
Further, the R-lobe contributes two larger loops
6, 13
 (Leu134-His159, Asn175-Ser205) 
reminiscent of the lid of the β-barrel hydrophobic core.
6
 The substrate binds along the active site 
cleft in an extended conformation
6, 27
 allowing its side chains to make alternate interactions with 
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Figure 1.3. [A] Pictorial representation of substrate binding sites according to Schechter 
 and Berger (1967). Enzyme pockets have been assigned as “S” and substrate peptide  
binding to corresponding pockets have been assigned as “P”. [B] Revised substrate 
 binding to papain like cysteine proteases. Papain numbering has been followed. Red- 
dotted line designates the bond that gets hydrolyzed by cysteine cathepsins.  
A 
B 
P4 P3 P2 P1 P1’ P2’ P3’ 
       





- Scissile bond 
S4            S3            S2           S1           S1´           S2´          S3´  
both lobes. Loops from left lobe accommodate P3, P1 and P2ʹ residues while loops from R-lobe 
engage in favorable binding interactions with P2 and P1ʹ.
6
 Among these subsites, S2 is a deep 
pocket whereas S1 and S1ʹ offer just a binding surface.
13
  Substrate binding beyond S3 and S2’ 
pocket do not include main chain interaction. Thus these regions are termed as areas but not as 
sites.
27 
 The substrate specificity of cysteine cathepsins are governed by physical interactions 
between enzyme and the substrates. Depending on the substrate cleavage site, cysteine 
cathepsins have been categorized as either an endopeptidase or an exopeptidase, or both (Figure 
1.4). Peptidase that cleaves within a substrate polypeptide chain has been coined as 
endopeptidase. On the other hand, exopeptidase hydrolyzes the terminal amino acid residue of 
7 
 
Figure 1.4. Pictorial representation of [A] endopeptidase, and [B] exopeptidase. Enzyme 
pockets have been assigned as “S” and substrate peptide binding to corresponding 
pockets have been assigned as “P”. Red-dotted line designates the bond that gets 
hydrolyzed by active site cysteine residue of cysteine cathepsins.  
A B 
  
the substrate peptide. Among cysteine cathepsins five of them are strict endopeptidase (cathepsin 
L, S, K, V and F) and three cathepsins serve exclusively as exopeptidase (cathepsin H, X and 
C)
7
. The peptidase activity of cathepsin O and W is yet to be explored. Depending on the cellular 
environment, cathepsin B can exert both endo and exopeptidase activity. Exopeptidases have 
further been categorized based on the nature of terminal amino acid residue and substrate peptide 
length that they cleave. Cathepsin B is a carboxypeptidase whereas cathepsin X acts as a carboxy 
monopeptidase.
19
 Cathepsin C is an aminodipeptidase
28





1.4 Mechanism of Proteolysis 
 The cysteine (Cys25) and the histidine (His163) residues of the active site of cathepsin L 
form an ion pair which confers enhanced nucleophilicity to cysteine residue. The mechanism of 
proteolysis by papain like cysteine cathepsins occurs in a step-wise process (Figure 1.5):  (1) 
Nucleophilic cysteine (Cys25) attacks the electrophilic  carbonyl center of substrate peptide and 
forms a tetrahedral anionic intermediate. This intermediate gets stabilized via oxyanion hole 
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interactions (2) His163 acts as a general acid and and assists cleavage of the peptide bond via 
protonation of leaving amide nitrogen. This leads to expulsion of the C-terminal peptide 
fragment, thereby facilitating the formation of thioacyl enzyme intermediate, and (3) Deacylation 











1.5 Localization and Physiological Significance  
 Originally, cysteine cathepsins were considered as redundant class of enzymes, primarily 
housed in lysosome, and involved in non-specific terminal protein degradation. Recent studies 
have revealed that cysteine cathepsins are not only expressed in lysosome but also in cytoplasm, 
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nucleus and in extracellular spaces as well. While, cathepsin B, L, V, O, H, C, X and F are 
ubiquitously expressed in human tissues, cathepsin K, S and W have a more restricted expression 
pattern. Variable expression patterns of cysteine cathepsins have implicated them to several 
important physiological processes. For example, cysteine cathepsins play important roles in 
immunological responses, prohormones activation, bone remodeling, angiogenesis and many 
other important physiological processes.
6
 Cathepsin L, F, S and V participates in MHC II-




 Cathepsin C activates 
various serine proteases and granzyme A and B that helps in limiting acute viral infection.
29
 
Cathepsin W is selectively expressed in natural killer cells and in CD8
+
 lymphocites and plays 
crucial role in cytotoxic killing of abnormal cells.
30
 Cysteine cathepsins are also involved in 





 and trypsin. Further, cathepsin B, L and K have been associated with 
thyroxine production
33
, while cathepsin H has been implicated in pulmonary surfactant-
associated protein processing in human lungs.
34
  
 Also, cysteine cathepsins are implicated in skeletal remodeling. Cathepsins K, L, F, S, V 
and B have been associated with elastin degradation with varying elastolytic activity.
35
 Cathepsin 
K is predominantly expressed in osteoclast and plays crucial role in bone resorption under 
normal and pathological conditions.
36
 
 In addition to aforementioned roles, cysteine cathepsins also take part in other 
physiological processes. Cathepsin L has been implicated to cell-cycle progression
37
 and 
keratinocyte differentiation and in hair follicle cycle.
38
 Moreover, cysteine cathepsins degrade 
proapoptotic Bcl-2 homolog protein bid and other antiapoptotic Bcl-2 family of proteins which 





1.6 Roles in Human Pathology 
 It is now well established that over-expression and aberrantly regulated activity of 
cysteine cathepsins play a major role in promoting many hallmarks of cancer.
39
 Often, these 
require cysteine cathepsins to be overexpressed in the extracellular space. Under normal 
physiology, extra cellular space is protected from cysteine cathepsins by neutral pH, endogenous 
inhibitors (for example, stefins, cystatins, kininogens, and thyropins)
6
 and reducing environment. 
Nevertheless, pericellular acidification and pathophysiologically reduced anticathepsin 
concentrations can help to enhance the activity of cathepsins.
7
 Elevated level of cathepsins 
expression and activity are the key mediators of invasive growth and angiogenesis during 
multistage tumorigenesis.
40
 Aberrantly active of cysteine cathepsins initiate proteolytic cascade 
that activate urokinase-type plasminogen activator, matrix metalloproteinases and plasminogen.
6
 
Moreover, these active proteases in conjunction with cysteine cathepsins degrade E-cadherin and 
extracellular matrix proteins that is key structural barrier that cells must cross to reach the 
vasculature.
41
 Subsequently, intracellular cysteine cathepsins aid the process by degrading 
collagen, as these cells accumulate extracellular matrix via endocytosis.
41c, 42
 
 The expression of cysteine cathepsins (e.g. B, F, and L) has indeed been found to be 
significantly upregulated in solid tumors from various origins, such as breast, skin, colorectal, 
pancreatic, ovarian, brain, head and neck.
39b, 43
 More importantly, a well-defined role for cysteine 
cathepsins in promoting cell invasion and cancer metastasis has recently emerged.
44
 A high level 
expression of cysteine cathepsin B was observed in invasive tumor cells derived from metastatic 
cancer patients of distinct origins.
45
  Deletion of either cysteine cathepsins, B, L or S led to 
decreased tumor invasion with tumors progressively returning to a more benign form.
43
 In a 
separate study, cysteine cathepsin X was able to compensate in part for the absence of cathepsin 
11 
 
B in a mouse model for mammary cancer.
44a
 In this study, inhibition of cysteine cathepsin X 
with a neutralizing antibody resulted in a drastic loss of invasive behavior in cathepsin B null 
cultured cells. E-cadherin, an important adherens junction protein that maintains cell-cell 
adhesion in epithelial cells, was recently identified as a direct proteolytic target of cysteine 
cathepsins B, L and S.
43
   Since it is well established that functional loss of E-cadherin promotes 
cell invasion and metastatic behavior of cancer cells, an effective inhibition of this family of 
enzymes is anticipated to provide significant therapeutic benefit in reducing metastatic potential 
of solid tumors.
46
 These studies have led to an interesting hypothesis that promotes a poly-
pharmacological approach to target pro-tumorigenic members of cysteine cathepsins collectively 
for the development of effective anti-cancer agents.  
1.7 Existing Classes of Reported Cysteine Cathepsin Inhibitors 
 Pathological significance has prompted cysteine cathepsins as promising drug targets. 
Although there are no drugs in use; few are in clinical trial. However, past three decades of effort 
has enabled deciphering key protein-ligand interaction that could initiate development of drug 
like molecules for cysteine cathepsins. Several different types of inhibitors have been developed 
which primarily targets the active site of cysteine cathepsins. Based on their mechanism of 
action, these inhibitors have been categorized in different classes. In general, the inhibitory 
scaffold is made of three components: (a) recognition region, which engage in physical 
interactions with enzyme binding pockets, (b) Address region, which generally confers 
additional interactions, and (c) electrophilic warhead, which traps the nucleophilic cysteine 
residue of active site. A cartoon diagram illustrating the design of inhibitor is shown below 




Figure 1.6. Pictorial representation of postulated inhibitor binding to enzyme. 
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1.8 Perspective of Synthesized Inhibitors and Activity-Based Probe 
 While numerous studies of cysteine cathepsins have clearly established them as important 
therapeutic targets for the development of anti-cancer agents, progress towards development of 
small molecule inhibitory agents that are non-peptidyl in nature remains slow. Currently, a 
majority of the reported inhibitory agents of cysteine cathepsins are peptidyl- or peptidomimetic-
based in nature, making them poorly cell permeable.
6
 Small molecule inhibitory agents of 
cysteine cathepsins that are uncharged and non-peptidyl in nature are therefore desirable so that 
they can be further developed as suitable biological inhibitory reagents, in addition to lead 





 = 0.86 nM (Cat L) 





= 2.5 nM (Cat K) 
Cell active 
Bicyclic ketone




designed to produce a covalent and irreversible chemistry with the catalytic active site 
nucleophilic Cys residue, then the inhibitors could also be developed as activity-based probes 
(ABPs) for the functional analysis of cysteine proteases in complex proteomes. Activity-based 
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Figure 2.1. Hybrid design of hypothesized aryl sulfonyloxirane as cysteine cathepsin inhibitor. 
2.1 Conceptual Design 
  The advent of E-64 from Aspergillus japonicus, an epoxysuccinyl-derived inhibitory 
agent, was a critically important stepping stone for deciphering the undocumented function of 
cysteine cathepsins family of enzymes.
69
 Although, E-64 is a generic non-selective inhibitor of 
cysteine cathepsins, structural investigation of the E-64-inhibited complex have subsequently led 
to the development of selective cysteine cathepsin B inhibitors (e.g. CA030 and CA074).
70
 The 
marked success of E-64 and its subsequent analogues as effective inhibitors of cysteine 
cathepsins relies on the exclusive reactivity of an active site cysteine residue with the 
electrophilic “warhead” epoxy group. The catalytic mechanism of cysteine cathepsins involves 
participation of this invariant and reactive cysteine residue.
71
 A close visual inspection of 
structure of CA030 and CA074 in complex with cysteine cathepsins revealed that there exists 
well-defined binding pockets, S2, and S1’, surrounding the S1 site (Schechter and Berger 
nomenclature)
72
 that prefer to accommodate aromatic hydrophobic groups.
70
 It was therefore 
hypothesized that an arylsulfonyl-substituted oxiranyl moiety could serve as a small molecule 
21 
 
covalent inactivator of cysteine cathepsins, targeting the key residues of the core enzyme active 
site (Figure 2.1). This approach envisions that (a) an appropriate binding of inhibitory 
compounds within the active site of cysteine cathepsin will allow the reactive Cys residue to be 
entrapped by the activated sulfonyloxirane group; and (b) the sulfonyl group will likely mimic 
the potential h-bonding interactions that the carbonyl group α to epoxy moiety exhibits in the 
CA-030-cysteine cathepsin B inhibited complex
70a
; and (c) the sulfonyl group will further 
enhance the electrophilicity of oxiranyl carbon, compared to a carbonyl group, thereby 
facilitating the entrapment of the active site Cys residue. If successfully demonstrated, this class 
of molecules could serve as a new type of chemical motif on which selective cysteine cathepsin 
inhibitors could be developed in future, exploiting the surrounding S3 and S’ pockets. Such a 





 Sulfonyloxiranes were synthesized according to scheme 2.1. Reaction of chloromethyl 
phenyl sulfone with corresponding aldehyde in presence of potassium hydroxide yield to 1
st 
generation of sulfonyl oxiranes
74
 (Scheme 2.1 A). 2
nd
 class of sulfonyloxiranes were synthesized 
using a different protocol (Scheme 2.1 B). Reaction of 2-bromoethanol with substituted 
thiophenol in presence of base yield to arylthioethanol. Oxidation of arylthioethanol by hydrogen 
peroxide (30%) provided 2-hydroxy arylsulfonylethane. Treatment of 2-hydroxy 
arylsulfonylethane with mesyl chloride in presence of triethylamine at 0
o
C leads to 
arylsulfonylethene. Further conversion of alkene intermediate to aryl sulfonyloxirane was carried 




generation of compounds were 











intermediate was achieved by reaction between thiophenol and allyl bromide in presence of 
potassium carbonate. MCPBA mediated oxidation of the acquired intermediate lead to aryl 
sulfonyloxirane with an extra methylene linker. Thiirane was eventually synthesized from the 
intermediate sulfonyloxirane using ammonium thiocyanate. 
2.3 Results and Discussion 
  A small library of sulfonyloxirane compounds was therefore synthesized. Cysteine 
cathepsin B, a promoter of cancer metastasis, was chosen as the initial inhibitory target to 
evaluate the efficacy of a time-dependent loss of enzyme activity (Table 2.1). The initial 
screening was performed by incubating a fixed concentration of compounds 1-13 with cathepsin 
B under pseudo-first order conditions. A small aliquot of the incubation mixture was withdrawn 
at a fixed time interval and the remaining cathepsin B activity was measured in a large volume of 
assay mixture (17.5 fold dilution) containing cathepsin B substrate. The IC50 values were 
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deliberately not estimated for this library, since they are not considered a good yardstick for 




 Compounds 1 and 2 which bear a non-polar 4-fluorophenyl and a propyl substituent 
respectively at the second carbon of the oxirane ring were non-inhibitory. This result indicated 
that a second substitution at the oxirane moiety in this class of molecules was perhaps 
detrimental to their inhibitory efficacies. Furthermore, compound 12, which incorporates a 
methylene linker between the arylsulfonyl group and oxirane moiety, was also inert. We 
surmised that the lack of reactivity of 12 could be due to lack of assistance from a general acid 
appropriately positioned in the cathepsin B active site to promote nucleophilic opening of 
oxirane ring by Cys29-Sγ residue. So, a thiirane analogue, 13, that potentially contains a better 
leaving group thiolate (compared to alkoxide in 12), was synthesized and was also found to be 
ineffective. This again indicated that appropriate positioning of arylsulfonyl group with respect 
to the reactive oxirane group within the cysteine cathepsin active site was critically important for 
its inhibition. Efforts became focused on synthesizing analogues of 2-(arylsulfonyl)oxiranes 
where functional variations of the aryl ring was further investigated.  














Table 2.1. Chemical structure of inhibitory library. 
































































































* NI : No measurable time-dependent inhibition 














Figure 2.3.  [A] Progress curves indicating a time-dependent loss of cathepsin B activity. 
Compound 5 was incubated with cathepsin B under pseudo-first order condition, and the 
progress curves were obtained at appropriate times of inactivation (red: 0 min, blue: 11 
min, green: 17 min, black: 25 min, and pink: 41 min) using a chromogenic substrate Z-
RR-para-nitroanilide. [B] Concentration-dependent loss of cathepsin B activity with time. 
The points are experimental, and the lines joining them are fitted to obtain the pseudo-first 







Figure 2.4.[A] Kitz-Wilson plot of 5-mediated cathepsin B inactivation kinetics. The data  
points are fitted to a line that yields (a) K
i
 = 86 ± 3 μM for the first equilibrium step of  
inhibitor binding, and (b) k
i
 = 0.21 ± 0.01 min
-1
 for the first order inactivation rate  
constant. [B] The rate of 5-mediated cathepsin B inhibition is decreased in the presence of  
leupeptin (40 nM; blue line), a known competitive inhibitor of cathepsin B, compared to  




cysteine cathepsin B activity. The effectiveness of compound 5 was evident from a progressive 
loss of enzyme activity when it was incubated with active cathepsin B (Figure 2.3). No gain in 
cathepsin B activity was observed even after dilution of 5-inactivated cathepsin B complex, 
thereby indicating that the mechanism of inhibition was perhaps covalent and irreversible in 
nature (data not shown). To assess the inhibitory efficacy, inactivation experiments were 
performed at appropriate concentrations of compound 5 under pseudo-first order conditions, and 
the experimental data thus obtained were analyzed using a simple two-step inhibition model 
(Figure 2.4.) 
 





Figure 2.5. A mass spectrometric analysis of 5-inhibited cathepsin B complex. A mass 
difference of 212.1 amu, consistent with the molecular weight of 5 (212.1), is observed in 
singly charged 5-inhibited cathepsin B complex (lower panel) compared to uninhibited 
cathepsin B enzyme (upper panel). This experiment demonstrates that the mechanism of  
5-mediated cathepsin B inhibition is covalent and irreversible in nature.  
 
where Ki represents the reversible equilibrium binding constant for the first step, and ki is the 
first order inactivation rate constant for the second irreversible step. To obtain these two 
parameters, the following procedure was adopted. The pseudo-first order rate constants of 
inactivation (kobs) were obtained at appropriate concentration of 5 ([I]>>[cathepsin B]), and a 
Kitz-Wilson analysis was performed to fit the experimentally obtained data (Figure 2.4.A).
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This procedure yielded the thermodynamic binding constant (Ki = 86 ± 3 μM) for the first 
equilibrium binding step, and the first order inactivation rate constant (ki = 0.21 ± 0.01 min
-1
) for 
the second irreversible step. We further investigated if the time-dependent inhibition of cathepsin 
B by 5 could be alleviated in the presence of a known active site-directed cathepsin B inhibitor, 
leupeptin (Ki = 5 nM) .
79
  This is mainly because if inhibitor 5 were to be an active-site directed 
agent, the rate of 5-mediated cathepsin B inactivation reaction would be retarded in presence of a 
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competitive inhibitor competing for the binding to the same active site.
80
 A protection from 
inhibition of cathepsin B inhibition was indeed observed in presence of leupeptin, thereby 
indicating that 5 occupied the core cathepsin B active site that harbors the low pKa nucleophilic 
Cys29 residue (Figure 2.4.B).  A MALDI-based mass spectrometric analysis of the 5-inhibited 
cathepsin B complex showed the expected mass increase of 212.1 amu in the cathepsin B 
protein. No further mass increase was observed even after prolonged incubation of 5 with     
cathepsin B. This result indicates that the mode of inhibition by 5 was indeed covalent and 
irreversible in nature and the stoichiometry of inhibition was likely 1:1 (Figure 2.5). This was 
important to establish since most cysteine cathepsins do contain multiple cysteines, in addition to 
the nucleophilic active site cysteine residue.
6
  
Computational Analysis of 5-inhibited cysteine cathepsin B complex 
 To understand the potential molecular interactions of 5 with cysteine cathepsin B in the 
covalently inhibited complex, computational modeling studies were performed. The CA073-
inhibited complex of cathepsin B (PDB id: 2DC6) was appropriately modified to incorporate the 
inhibitor 5 covalently linked to Cys29-Sγ of cathepsin B active site. A molecular dynamic 
simulation (100 ps) was performed on the inhibitory complex and the trajectories of the 
molecular dynamics simulation were analyzed. Several interactions between the inhibitor 5 and 
cathepsin B active site were noteworthy (Figure 2). While the O3 of sulfonyl oxygen formed a h-
bond (3.4 Å) with the side chain of Gln23-Nε – a key oxyanion hole residue, its O2 atom was 
engaged in a robust hydrogen  bond interactions (2.8 Å) with a tightly-bound active site water 
molecule (Wtr12). The OH group of inhibitor was also stabilized with two h-bond interactions, 
one with the backbone carbonyl of a S2 site residue Gly198 (3.1 Å) and the other with an active 
site water (Wtr56)  molecule (2.5 Å). The phenyl moiety of the inhibitor was found to be 
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Figure 2.6.Stereoscopic view of the energy-minimized structure of the covalently 
modified 5-cathepsin B complex. The low pKa active site Cys29 residue is the  
site for 5-mediated covalent modification. For clarity, only the inhibitor 5 (yellow) 
and the key cathepsin B active site residues are shown. The key h-bonding 
distances of 5 with cathepsin B are shown in green. The intramolecular h-bonding 
interactions among cathepsin B active site residues near the inhibitor binding site 
are depicted in red (heavy atom h-bond donor and acceptor atoms cut off is 3.6 Å). 
The position of the primed and non-primed binding pockets on cathepsin B surface 
is shown in pink text with underline. 
 
involved in a hydrophobic interaction with a non-polar patch containing Met196, Gly197, and 
Gly198 residues of S2 pocket. In addition, the ortho-ethyl group interacted with CH-π 
interactions with the aromatic side chains of Trp221 and His110 from S2’ pocket, albeit 
weakly.
81
 A conclusive design of future inhibitory ligand that are selective towards individual 
members of the cysteine cathepsin family will require structural elucidation of 5-inhibited 
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cysteine cathepsin complex using x-ray crystallography. Our modeling study suggests that ortho-
substituted aryl groups containing a negatively charged group could prove to be selective 
inhibitory agents towards cathepsin B. Notably, cathepsin B is a unique member of cysteine 
cathepsins in that it exhibits endopeptidase, peptidyldipeptidase and carboxypeptidase 
activities.
82
 This broad substrate specificity of cathepsin B has been ascribed to its unique 
structural feature that contains a flexible occluding loop (residues 104-126). Since Try221, 
His110, and His111 are part of this occluding loop, securing potential interactions from this loop 
could result in enhanced selectivity and potency towards cathepsin B. Such features could be 
exploited in designing selective inhibitors of cathepsin B. 
Compound 5 is inert to external nucleophile and inhibits cysteine cathepsins 
selectively. 
 To evaluate if the presence of an external nucleophile could compromise the inhibitory 
efficacy of 5, we carried out cathepsin B inactivation kinetics in the presence of a strong 
nucleophile, azide ion (1 mM). No measurable change in inactivation kinetics was evident 
thereby indicating that compound 5 is relatively inert to an external nucleophile and unleashes its 
covalent reactivity only upon binding to the cathepsin B active site (data not shown). The 
selectivity of inhibition of compound 5 towards cysteine cathepsins was investigated next. To do 
so, a panel of distinct family of enzymes were chosen and their inhibition by 5 was assessed 





 Table 2.2. Selectivity of inhibition of compound 5 towards cysteine cathepsins as assessed by 
the 2
nd





Calculated from the ki and Ki parameters obtained using Kitz-Wilson Analysis. 
b
Determined by 
measuring pseudo-first order rate constant of inactivation kobs first and dividing the kobs by the 
inhibitor concentration. 
c
NI: No apparent time-dependent inhibition even at a concentration as 
high as 1 mM during a 1-hour inactivation reaction. 
other two prominent members of cysteine cathepsins, namely cathepsin F and cathepsin S, an 
aspartyl-utilizing cathepsin D was only weakly (1/38
th
 fold compared to cysteine cathepsin B) 
inhibited. Cathepsin G and trypsin protease that use a Ser nucleophile for catalysis remained 
inert to inhibition. These experiments suggested that compound 5 is selective towards cysteine 
cathepsins that utilize the uniformly conserved and reactive Cys residue for catalysis. The ability 
of compound 5 to inhibit protein tyrosine phosphatases (PTPs) was also evaluated. This enzyme 
Enzyme (Enzyme Family) 2
nd






Cathepsin B (Cysteine Cathepsin)                                         2441 ± 202
a
 
Cathepsin F (Cysteine Cathepsin)                                          1300 ± 208
b
 
Cathepsin S (Cysteine Cathepsin)                          1196 ± 96
b
 
Cathepsin D (Aspartyl Cathepsin)                                          65 ± 5
b
 
Cathepsin G (Serine Cathepsin)                                              NI
c
 
Trypsin (Serine Protease)                                                        NI
c
 





utilizes a low pKa Cys residue in nucleophilic catalysis. Although 2-(arylsulfonyl)-oxiranes were 
previously reported to be modest inhibitors of PTPs
75
, this enzyme also remained inert to 
inhibition by 5. This outcome was observed with the prototypical PTP, hPTP1B, even at a 
concentration as high as 1 mM and after a prolonged incubation of one hour. While a conclusive 
analysis of this selectivity pattern towards cysteine cathepsins will require structural elucidation 
in the 5-inhibited cathepsin B complex, it appears that the presence of an ethyl group at the ortho 
position of 2-(phenylsulfonyl)oxirane is significantly favored for binding at the cysteine 
cathepsin active site.  
2.4 Demonstration of Intracellular Activity of Aryl Sulfonyloxiranes 
 Before proceeding to evaluate the cellular efficacy of 5 to inhibit cysteine cathepsins in 
human cells, it was important to establish its hydrolytic stability at physiological pH. This 
consideration was prompted by the oxirane functionality in 5 which could become hydrolytically 
unstable as a result of the adjacent electron-withdrawing sulfonyl moiety. This could render the 
inhibitor unsuitable for biological applications. Using NMR-based experiments, the half life of 5 
at physiological pH (pH = 7.4) was found to be 3.6 hours (Experimental section. Figure 2.10). 
This study suggested that compound 5 was relatively stable at physiological pH, and therefore 
could be used as an important tool in biological applications.  
 Cysteine cathepsins play important functional roles in both intracellular and extracellular 
signaling events.
83
 Contrary to popular belief, recent studies strongly suggest that within the cell, 
active cysteine cathepsins play regulatory roles in distinct cellular compartments other than 
lysosomes, such as nucleus, mitochondrial matrix, cytoplasm, and plasma memebrane.
84
 For 
example, a mis-regulated and an enhanced proteolytic activity of cytoplasmic cysteine cathepsins  
34 
 
have shown to be linked to tumor invasion.
83
 Indeed, the invasion potential of both human 
melanoma and prostate carcinoma cells was found to be significantly reduced only when these 
cells were subjected to cell membrane permeable cysteine cathepsin inhibitors, thereby 
suggesting the importance of intracellular cathepsins and their effective inhibition.
85
 Similarly, a 
study by Sloane et al. in human breast carcinoma BT549 cells suggested that only cell-permeable 
cysteine cathepsin inhibitors were able to reduce the intracellular proteolysis in these cells.
42c
 
These investigations together underscore the importance of developing non-peptidyl and cell 
permeable small molecule inhibitors of cysteine cathepsins; so that their precise function can be 
annotated in both normal physiology and human diseases. Unfortunately, cell-permeable and 
non-peptidyl inhibitory agents of cysteine cathepsins remain scarcely available today. 
Thus in an initial approach, we assessed whether 5 had the potential to inhibit 
intracellular cysteine cathepsin B activity in living cells. The metastatic MDA-MB-231 human 
breast cell line was chosen for this study since it has been shown that cysteine cathepsin B 
activity is upregulated in these cells.
86







), previously employed in cell-based experiments, cell-based 
experiments, was chosen for this study.
87
 While efficient proteolysis of the substrate was evident 
in control MDA-MB-231 cells, a significant loss of intracellular cathepsin B activity was 
observed in 5-treated cells (Figure 2.7.A). Furthermore, intracellular cathepsin B activity was 
shown to decrease in a dose-dependent manner (Figure 2.7.B). 
In a second approach, the usefulness of 5 to inhibit cellular cysteine cathepsin activity in 
cells was also investigated using a physiologically relevant proteolytic protein target of cysteine 
cathepsin B and S, namely E-cadherin, an adherens junction protein.
43
 The integrity of this 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 While it has been shown that a mere loss of cell-cell contacts alone is not 
sufficient to promote metastasis, a loss of E-cadherin alone has been shown to be sufficient to 
induce this behavior through epithelial-to-mesenchymal transition (EMT), enhanced motility, 
resistance to apoptosis, and invasiveness.
89
 The majority of human tumors are carcinomas that 
originate from cells of epithelial tissues where a complete or a partial loss of E-cadherin occurs 
as the tumor progressively becomes malignant.
90
 Thus, the loss of E-cadherin has been directly 
linked to invasive migratory behavior of cancer cells.
89, 91
 In a study involving metastatic MDA-
MB-231 breast cancer cells which expresses very low levels of E-cadherin,
90c
 the re-expression 
of E-cadherin led to the restoration of normal E-cadherins-mediated cell-cell junctions, and a 
reversion to a normal epithelial morphology.
92
 We therefore evaluated the levels of E-cadherin in 
MDA-MB-231 cells using an E-cadherin antibody in the presence and absence of inhibitor 5. As 
anticipated, a dose-dependent increase in the levels of E-cadherin was observed in a population 
of 5-treated MDA-MB-231 cells, as compared to control cells treated only with DMSO (Figure 
2.8.A and B).  It should also be noted that the overall cellular morphology of metastatic MDA-
MB-231 cells also changed upon inhibitory treatment (Figure 2.7.A and 2.8.A). This perhaps is 
not too surprising since cellular enrichment of E-cadherin is known to have a direct impact on 
cellular morphology.
88a, b
 Further experiments will be required to investigate the molecular basis 
of altered cellular morphology in MDA-MB-231 cells upon inhibitory treatment. A western blot 
analysis of 5-treated MDA-MB-231 cells was also performed that exhibited an enrichment of E-
cadherin levels in 5-treated cells, as compared to the control cells (Appendix D). Collectively, 
these studies demonstrated that 5 was effective in inhibiting the intracellular activity of cysteine 




Figure 2.9. The effect of cysteine cathepsin inhibitor 5 on the cell-
migratory behavior of metastatic breast cancer MDA-MB-231 cells. 
The cell migration phenotype was reduced upon treatment with 5 at 
10 μM and 20 μM respectiviely, compared to control. Each reported 
change in area value is the average of triplicate measurements with 
the corresponding standard deviation value. 
 An enrichment of E-cadherin levels as a result of inhibition of cysteine cathepsins by 5 is 
anticipated to exhibit a reduced cell migratory behavior.
93
 To investigate this, the cell motility 
assay was carried out 
in presence and 
absence of inhibitor 5 
(control, 0.05% 
DMSO) on highly 
metastatic breast 
cancer MDA-MB-
231 cells. As 
anticipated, a dose-
dependent decrease 
in cell migratory 
behavior of 
metastatic MDA-
MB-231 cells was 
observed (Figure 
2.9). This experiment supported the notion that compound 5 inhibits cell migration potential of 
these highly metastatic cells. Future experiments will be planned to further optimize the 
inhibitory and anti-cell migratory potential of this class of compounds.  
2.5 Conclusions. 
 We have developed a new class of small molecule inhibitors of cysteine cathepsins. A 
detailed kinetic and mass spectrometric analysis of cysteine cathepsin B inhibition by 5 was 
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performed to determine the kinetic parameters and mode of inhibition. The covalent inhibition of 
compound 5 was found to be selective towards cysteine cathepsins. The mechanistically distinct 
enzymes, such as aspartyl cathepsin D, serine cathepsin G, serine protease trypsin and a low pKa 
cysteine-containing enzyme protein tyrosine phosphatase 1B, were not inhibited by 5. Molecular 
modeling studies of 5-inhibited cysteine cathepsin B complex indicated that 5 interacted 
favorably with the key active site residues surrounding S1 and S2 pockets. The inhibitor 5 was 
shown to be relatively stable to hydrolysis, cell-permeable, and effective in inhibiting 
intracellular cysteine cathepsin B activity in metastatic human breast carcinoma MDA-MB-231 
cells. We also demonstrated that compound 5 was effective in reducing the migratory potential 
of the metastatic MDA-MB-231 breast cancer cell lines. This class of inhibitory agents could 
find applications in construction of selective activity-based probe of cysteine cathepsins, and in 













2.6.1 Synthesis  
General.  
13
C NMR and 
1
H spectra were recorded on a Brucker DPX 400 MHz FT NMR 
with automatic sample changer. Chemical shifts (δ) are reported in parts per million (ppm) and 
referenced to CDCl3 (7.26 ppm for 
1
H and 77.0 ppm for 
13
C), DMSO (2.50 ppm for 
1
H and 39.5 
ppm for 
13
C), (CD3)2CO (2.05 ppm for 
1
H and 29.9, 206.7 for 
13
C) and CD3OD (4.87, 3.31 for 
1
H 
and 49.1 for 
13
C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are 
abbreviated as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), 
and multiplet (m). The following materials were purchased from Matrix Scientific (Columbia, 
SC, USA) m-thiocresol, 3-methoxybenzenethiol, 3,5-dichlorothiophenol, 2,5-
dimethylthiophenol, 4-(trifluoromethoxy)thiophenol, 2-ethylthiophenol and 2,5-
dimethoxythiophenol. Thiophenol, 2-naphthalenethiol, chloromethyl phenyl sulfone, 4-
fluorobenzaldehyde, butyraldehyde, disodium salt of silica gel (Merck, grade9385, 230-400 
mesh, 60 Ǻ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide, 
hydrochloric acid, sodium chloride, sodium sulfate, ammonium chloride, and solvents were 
purchased from Fisher Scientific Inc (Pittsburgh, PA, USA).  
2-(4-fluorophenyl)-3-(phenylsulfonyl)oxirane (1): The synthesis of this compound was 
achieved in a single step by appropriate modification of a published protocol
74
. The procedure 
involved a 1-hour long reaction of 4-fluorobenzaldehyde with (chloromethylsulfonyl)benzene at 
room temperature in the presence of a phase transfer catalyst, tetra-n-butylammonium bromide 
(10 mol%), in toluene and potassium hydroxide solution. The final purification was performed 
using silica gel-based flash chromatography procedure that yielded compound 1 as a white solid. 
41 
 
Rf = 0.28 Hexane: EtOAc (9:1). Yield: 90%. 
1
H NMR (400 MHz, (CDCl3) δ ppm: 4.16 (d, J = 
1.4 Hz, 1H), 4.58 (d, J = 1.4 Hz, 1H), 7.06 (m, 2H), 7.24 (m, 2H), 7.64 (m, 2H), 7.75 (m, 1H), 
7.99 (m, 2H). 
13
C NMR (500 MHz, CDCl3); δ ppm 56.94, 70.95, 116.11 (d, JC-F = 22.3 Hz, 2C 
intensity),  128.00 (d, JC-F = 8.5 Hz, 2C intensity), 128.53 (d, JC-F = 3.3 Hz, 1C), 128.88 (2C 
intensity), 129.56 (2C intensity), 134.70, 136.77,163.49 (d, JC-F = 250 Hz, 1C intensity). LRMS 
[ESI-MS +ve] calculated for (C14H7FO3S + Na): 301.03, observed: 301.25.  
2-(phenylsulfonyl)-3-propyloxirane (2): This compound was synthesized using the same 
synthetic protocol as outlined in the synthesis of 1. The final purification was performed using 
silica gel-based flash chromatography procedure that yielded compound 2 as a viscous oil. Rf = 
0.22 Hexane: EtOAc (9:1). Yield: 85%. 
1
H NMR (500 MHz, CDCl3) δ ppm: 0.94 (t, J = 7.4 Hz, 
3H) 1.47 (m, 2H), 1.57 (m, 1H), 1.66 (m, 1H), 3.63 (m, 1H), 3.90 (d, J = 1.6 Hz, 1H), 7.58 (m, 
2H), 7.68 (m, 1H), 7.91 (m, 2H). 
 13
C NMR (500 MHz, CDCl3) δ ppm: 13.63, 18.93, 32.22, 
57.79, 68.30, 128.69 (2C intensity), 129.41 (2C intensity), 134.43, 137.08.  LRMS [ESI-MS +ve] 
calculated for (C11H14O3S + Na): 249.06, observed: 249.25 
2-(4-chlorophenylsulfonyl)oxirane (3): This compound was synthesized by following an earlier 
published protocol.
75
 The final purification was performed using silica gel-based flash 
chromatography procedure that yielded compound 3 as a white powder. Rf = 0.50 (hexane/ 
EtOAc = 9/1). Yield: 63%. 
1
H NMR (400 MHz, CDCl3) δ ppm: 3.07 (dd, J = 5.4 and 3.7 Hz, 
1H), 3.37 (dd, J = 5.4 and 2.1 Hz, 1H), 4.05 (dd, J = 3.7 and 2.1 Hz, 1H), 7.52 (d, J= 8.60 Hz, 
2H), 7.81 (d, J= 8.60 Hz, 2H). 
13
C NMR (400 MHz, CDCl3) δ ppm: 45.54, 63.25, 129.84 (2C 
intensity), 130.31 (2C intensity), 135.25, 141.55. LRMS [ESI-MS +ve] calculated for 
(C8H7ClO3S + H): 218.99, observed: 219.00 
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2-((4-trifluoromethoxy)phenylsulfonyl)oxirane (4). This compound was synthesized by 
following a published protocol.
75
 The final purification was performed using silica gel-based 
flash chromatography procedure that yielded compound 4 as white semi-solid. Rf = 0.29 (hexane/ 
EtOAc = 19/1). Yield: 40%. 
1
H NMR (400 MHz, CDCl3) δ ppm: 3.16 (dd, J = 5.3 and 3.6 Hz, 
1H), 3.46 (dd, J = 5.3 and 2.0 Hz, 1H), 4.14 (dd, J = 3.6 and 2.0 Hz, 1H), 7.43 (d, J= 8.90 Hz, 
2H), 8.01 (d, J = 8.8 Hz, 2H). 
13
C NMR (400 MHz, CDCl3) δ ppm: 45.58, 63.24, 120.20(q, JC-F = 
283 Hz), 121.10 (2C intensity), 131.22 (2C intensity), 134.99, 153.71. LRMS [ESI-MS +ve] 
calculated for (C9H7F3O4S + H): 269.01, observed: 269.00. 
2-(2-ethylphenylsulfonyl)oxirane (5). This compound was synthesized by following a 
published protocol.
75
 The final purification was performed using silica gel-based flash 
chromatography procedure that yielded compound 5 as a pale yellow viscous oil. Rf = 0.28 
(hexane/ EtOAc = 19/1). Yield: 72%. 
1
H NMR (400 MHz, CDCl3) δ ppm: 1.32 (t, J= 7.4 Hz, 
3H), 3.09 (q, J = 7.4 Hz, 2H), 3.11 (DD, J = 5.4 and 3.7 Hz, 1H), 3.40 (dd, J = 5.4 and 2.1 Hz, 
1H), 4.19 (dd, J = 3.8 and 2.1 Hz, 1H), 7.42 (m, 2H), 7.61 (td, J = 7.7 and 1.2 Hz, 1H), 7.99 (dd, 
J = 8.0 and 1.2 Hz, 1H). 
13
C NMR (400 MHz, CDCl3) δ ppm: 16.15, 26.59, 44.87, 63.65, 126.64, 
130.81, 131.33, 134.57, 134.92, 145.86. LRMS [ESI-MS +ve] calculated for (C10H12O3S + H): 
213.06, observed: 213.08 
2-(m-tolylsulfonyl)oxirane (6). This compound was synthesized by following a published 
protocol.
75
 The final purification was performed using silica gel-based flash chromatography 
procedure that yielded compound 6 as a colorless viscous oil. Rf = 0.39 (hexane/ EtOAc = 9/1). 
Yield: 70%. 
1
H NMR (400 MHz, CDCl3) δ ppm: 2.46 (s, 3H), 3.12 (dd, J = 5.4 and 3.7 Hz, 1H), 




C NMR (400 MHz, CDCl3) δ ppm: 139.82, 136.66, 135.39, 129.33, 129.06, 125.92, 63.25, 
45.35, 21.34.  LRMS [ESI-MS +ve] calculated for (C9H10O3S + H): 199.05, observed: 199.25 
2-(2,5-dimethylphenylsulfonyl)oxirane (7): This compound was synthesized by following an 
earlier published protocol.
75
 The purification using silica gel column chromatography yielded 7 
as colorless viscous oil. Rf = 0.32 (hexane/ EtOAc = 9/1). Yield: 68%. 
1
H NMR (400 MHz, 
CDCl3) δ ppm: 2. 39 (s, 3H), 2.67 (s, 3H), 3.10 (dd J = 5.3 and 3.7 Hz, 1H), 3.88 (dd, J = 5.3 and 
2.1 Hz, 1H), 4.18 (dd, J = 3.7 and 2.1 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 
7.79 (s, 1H). 
13
C NMR (400 MHz, CDCl3) δ ppm: 20.33, 20.80, 44.68, 63.36, 131.03, 132.83, 
134.87, 135.22, 136.31, 136.78. LRMS [ESI-MS +ve] calculated for (C10H12O3S + H): 213.06, 
observed: 213.08 
2-(3-methoxyphenylsulfonyl)oxirane (8): This compound was synthesized by following a 
published protocol.
75
 The purification using silica gel column chromatography yielded 8 as a 
brownish viscous oil. Rf = 0.27 (hexane/ EtOAc = 9/1). Yield: 70%. 
1
H NMR (400 MHz, CDCl3) 
δ ppm: 3.13 (dd, J = 5.4 and 3.7 Hz, 1H), 3.42 (dd, J = 5.4 and 2.0 Hz, 1H), 3.89 (s, 3H), 4.13 
(dd, J = 3.7  and 2.0 Hz, 1H), 7.23 (ddd, J =7.6, 2.5, and 1.9 Hz, 1H), 7.42 (dd, J = 1.9 and 1.6 
Hz, 1H), 7.52 (m, 2H). 
13
C NMR (400 MHz, CDCl3) δ ppm: 160.15, 137.94, 130.54, 121.27, 
120.94, 112.93, 63.25, 55.78, 45.31. LRMS [ESI-MS +ve] calculated for (C9H10O4S + H): 
215.04, observed: 214.83 
2-(2,5-dimethoxyphenylsulfonyl)oxirane (9): This compound was synthesized by following a 
published protocol.
75
 The purification using silica gel column chromatography yielded 9 as a 
white semi-solid. Rf = 0.24 Hexane: EtOAc (9:1). Yield:  78 %. 
1
H NMR (500 MHz, (CD3)2CO) 
δ ppm: 3.19 (dd, J = 5.6 and 3.7 Hz, 1H), 3.31 (dd, J = 5.6 and 2.0 Hz, 1H), 3.83 (s, 3H), 3.97 
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(s, 3H), 4.75 (q, J = 3.7 and 2.0 Hz, 1H), 7.28 (m, 3H).
13
C NMR (500 MHz, (CD3)2CO) δ ppm: 
44.56, 55.46, 56.45, 56.47, 62.31, 114.07, 114.71, 121.83, 151.82, 153.37. LRMS [ESI-MS +ve] 
calculated for (C10H12O5S + H): 245.05, observed: 245.08 
2-(3,5-dichlorophenylsulfonyl)oxirane (10): This compound was synthesized by following a 
published protocol.
75
 The purification using silica gel column chromatography yielded 10 as a 
white powder. Rf = 0.67 (hexane/ EtOAc = 9/1). Yield: 45%. 
1
H NMR (400 MHz, CDCl3) δ 
ppm: 3.18 (dd, J = 5.4 and 3.7 Hz, 1H), 3.48 (dd, J = 5.4 and 2.0 Hz, 1H), 4.16 (dd, J = 3.7 and 
2.0 Hz, 1H), 7.69 (t, J =1.8 Hz, 1H), 7.82 (d, J=1.8 Hz, 2H).
13
C NMR (400 MHz, CDCl3) δ ppm: 
45.54, 63.19, 127.18 (2C intensity), 134.61, 136.54 (2C intensity), 139.72. LRMS [ESI-MS +ve] 
calculated for (C8H6 Cl2O3S + Na): 274.93, observed: 275.00 
2-(naphthalen-3-ylsulfonyl)oxirane (11): This compound was synthesized by following a 
published protocol.
75
 The purification using silica gel column chromatography yielded 11 as a 
white powder. Rf = 0.27 (hexane/ EtOAc = 19/1). Yield: 78%. 
1
H NMR (400 MHz, CDCl3) δ 
ppm:  3.15 (dd, J = 5.4 and 3.7 Hz, 1H), 3.47 (dd, J = 5.4 and 2.1 Hz, 1H), 4.19 (dd, J = 3.7 and 
2.1 Hz, 1H), 7.66 (m, 1H), 7.72 (m, 1H), 7.91 (dd, J = 8.6 and 1.8 Hz, 1H), 7.96 (d, J = 8.6 Hz, 
1H),  8.03 (dd, J = 8.4 and 1.0 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.53 (d, J = 1.0 Hz, 1H).
13
C 
NMR (400 MHz, CDCl3) δ ppm:  45.43, 63.39, 123.09, 127.85, 128.06, 129.60, 129.71, 129.76, 
131.02, 132.20, 133.69, 135.75. LRMS [ESI-MS +ve] calculated for (C12H10O3S + H): 235.05, 
observed: 235.08 
2-((phenylsulfonyl)methyl)oxirane (12): This compound was synthesized by following the 
literature-reported protocol
95
 and its characterization was found to be consistent with the 





2-((phenylsulfonyl)methyl)thiirane (13): This compound was synthesized by following the 
literature-reported protocol
95
 and its characterization was found to be consistent with the 
previously reported NMR spectra.
97
  
2.6.2 Enzymology, physiochemical, and mass spectrometric studies 
General. Following enzymes and their substrates were purchased from Enzo Life Sciences 
(Farmingdale, NY, USA): cathepsin B (BML-SE198), cathepsin D (BML-SE199), cathepsin S 
(BML-SE453), cathepsin F (BML-SE568), cathepsin G (BML-SE283), human PTP1B (BML-
SE332), Z-Arg-Arg-pNA (BML-P138), Z- Arg-Arg-AMC (BML-P137), Z-Phe-Arg-AMC 
(BML-P139), Suc-Ala-Ala-Pro-Phe-pNA (BML-P141), Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-
Leu-Lys(Dnp)-D-Arg-NH2 (BML-P145), Z-Val-Val-Arg-AMC (BML-P199). N-alpha-benzoyl-
DL-arginine-p-nitroanilide (BAPNA) (B4875), trypsin (T1426), leupeptin, para-
nitrophenylphosphate and bovine serum albumin (A2153) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). All the biological grade buffers were used and were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). All enzyme kinetics experiments (unless otherwise stated) 
were carried out at 30 °C in appropriate buffer condition with 5% DMSO concentration. The 
mass spectra were acquired using a MALDI-microMX mass spectrometer (Waters Corp, 
Milford, MA) instrument equipped with an N2 laser operating at 10 Hz, using delayed extraction 
and positive ion linear mode analysis. For measuring the initial rates of enzyme catalyzed 
reaction, a temperature-controlled steady-state arc lamp fluorometer equipped with Felix 32 
software (Photon Technology Instrument, Birmingham, NJ, USA) and a UV-Vis 
spectrophotometer (Model λ25; Perkin Elmer Inc., Waltham, MA, USA) was used. 
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Methodologies for assessing time-dependent inactivation of cysteine cathepsin B and 
inhibitor screening procedure: 
  The inactivation reaction of human liver cathepsin B (net 175 nM) with inhibitor was 
performed under pseudo first  order condition ([I]>>[E]) in a 0.5 ml eppendorf tube maintained 
at 30 
°
C in a temperature controlled bath. Freshly made Inhibitor stock solution (in DMSO) was 
used for each experiment. A previously reported cathepsin B assay procedure was employed.
98
 
Cathepsin B enzyme was first activated for 10 minutes in sodium phosphate buffer (100 mM, pH 
6.0) containing 5 mM DTT and 1 mM Na2EDTA. The inactivation reaction was initiated by the 
addition of inhibitor where DMSO concentration was maintained at 5%. After suitable time 
intervals, an aliquot of 10 μl of incubation mixture was withdrawn and added to an assay mixture 
(net assay volume 175 μl) that contained 3mM of Z-RR-pNA (Km = 0.9 mM) substrate at 30 
°
C. 
A progress curve was recorded at 405 nM, and the enzyme activity was determined by measuring 
the initial rates of substrate turnover. For initial screening experiments, the assay protocol 
remained the same except that the concentration of all inhibitors was fixed at 500 μM and the 
residual enzyme activity was measured after 10 minutes of reaction. 
Method for estimation of kinetic parameters for 5-mediated cathepsin B inhibition:  
 To obtain Ki and ki parameters for the two step inhibition model, the following procedure 
was adopted. A sequence of independent cathepsin B inactivation experiments were performed at 
25, 50, 75, 100, and 150 μM of 5 under pseudo-first order condition ([I]>>[Cathepsin B]) and 
enzyme activities were monitored at appropriate time intervals. The data thus obtained at each 





At = enzyme activity at time t of cathepsin B inactivation, Af = final cathepsin B activity at 
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infinite time of inactivation, A0 = initial enzyme activity at zero time of inactivation, and kobs = 
pseudo-first order rate constant of inactivation. Kitz-Wilson analysis is then performed to 
estimate the reversible equilibrium binding constant Ki for the first step, and the first order 
inactivation rate constant (ki) for the second irreversible step, as described elsewhere.
78
 For, 
demonstration that compound 5 is active site-directed, the inactivation reaction of 5 with 
cathepsin B was performed in presence of an established competitive inhibitior of cathepsin B, 
leupeptin (40 nM) and the residual cathepsin B activity was measured, as described above. Such 
a methodology has been previously utilized to demonstrate the active site-directed nature of 
inhibition for previously uncharacterized covalent and irreversible inhibitory agents.
80, 99
 
Cathepsin F inhibition assay: 
  A previously reported enzyme assay procedure was adopted with appropriate 
modifications.
100
 The enzyme was activated for 10 minutes in 50 mM potassium phosphate 
buffer at pH 6.5 containing 2.5 mM DTT, 2.5 mM Na2EDTA, and 1.0 mg/ml BSA at 25 °C. The 
inactivation reaction was initiated by addition of inhibitor 5 to activated human cathepsin F (net 
1.1 nM). After suitable time intervals, an aliquot of 10 μl of incubation mixture was withdrawn 
and the enzyme activity was measured in an assay buffer (net 175 μl) containing 3 μM of Z-FR-
AMC fluorogenic substrate (Km = 0.44 μM) at 25
°
C.  
Cathepsin S inhibition assay: 
  For assaying cathepsin S activity, a previously published protocol was followed with 
appropriate modification.
101
 Thus, cathepsin S enzyme was activated first in the 100 mM 
potassium phosphate buffer (pH 6.5) containing 5 mM DTT, 5 mM Na2EDTA for 10 minutes. 
The inactivation reaction of human Cathepsin S (net 134.6 nM) with inhibitor 5 (75 μM) was 
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initiated. After suitable time intervals, an aliquot of 3 μl of incubation mixture was withdrawn 
and the enzyme activity was measured in assay buffer (175 μl; 8% DMSO) containing 250 μM 
of Z-VVR-AMC (Km >100 μM
102
; Ex/Em: 365/440 nm) fluorogenic substrate.  
Cathepsin G inhibition assay:  
 A previously reported assay conditions were followed.
103
 The enzyme was activated in 20 
mM Tris-HCl buffer (pH 7.4) containing 500 mM NaCl for 15 minutes. The inactivation reaction 
of human Cathepsin G (net 7.66 nM) with inhibitor 5 was initiated. After suitable time intervals, 
an aliquot of 10 μl of incubation mixture was withdrawn and the enzyme activity was measured 
in assay buffer containing 3.4 mM Suc-AAPF-pNA cathepsin G substrate (Km= 1.7 mM). 
Cathepsin D inhibition assay:  
 The enzyme was activated in 50 mM sodium acetate buffer (pH = 4) containing 5 mM 
DTT and 1 mg/ml bovine serum albumin. The inactivation reaction of human Cathepsin D (net 
20 nM) with inhibitor was initiated. After suitable time intervals, an aliquot of 1 μl of incubation 
mixture was withdrawn and added to an assay mixture (net assay volume of 175 μl) that 
contained 40 μM of Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 
[Mca=(7-methoxycoumarin-4-yl)acetyl] cathepsin D substrate (Km = 3.7μM). Enzyme activity 
was monitored by measuring fluorescent enhancement over the time.  
Serine protease (trypsin) inhibition assay:  
 The assay procedure was adopted from an earlier published protocol 
104
. Trypsin enzyme 
solution was freshly made using 1 mM HCl just before the inactivation reaction. Inactivation 
reaction was initiated by the addition of inhibitor to a pre-activated trypsin (net concentration of 
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190-200 U/μl). After suitable time intervals, an aliquot of 2 μl incubation mixture were 
withdrawn and added to a 67 mM sodium phosphate assay buffer (net assay volume of 175 μl) 
which contained 3 mM N-alpha-benzoyl-DL-arginine-p-nitroanilide (BAPNA, Km = 0.94 mM) 
as a substrate. Enzyme activity was monitored by measuring the initial rate of substrate 
consumption at 410 nm. 
Protein tyrosine phosphatase 1B (PTP1B) inhibition assay:  
 The time-dependent inactivation kinetics of 5 with PTP1B was performed as described 
before.  
Mass-spectral studies:  
 Cathepsin B was activated and incubated with inhibitor under conditions similar to those 
used for kinetics studies for 10 minutes. Both 5-inhibited cathepsin B inhibitory complex and 
control (5% DMSO) were prepared for matrix-assisted laser desorption/ionization mass 
spectrometry using the ultra-thin layer essentially as published.
105
 Samples were saturated in a 
1:9 ratio with a saturated solution of recrystallized α-cyano-4-hydroxycinnamic acid in 50% 
formic acid/ 33% isopropyl alcohol/ 17% water (v/v/v; Fisher Scientific- all HPLC grade). 
Acceleration potential of 12,000 V and an extraction pulse of 1,950 V with a delay time for 410 
ns were used. Spectra were smoothed and baseline corrected using MassLynx (Waters Corp) and 
calibrated pseudo-internally using equine apomyoglobin. 
Hydrolytic stability of inhibitor 5:  
 To study the hydrolytic stability of compound 5, NMR experiment was carried out in 
following manner. First, sodium phosphate buffer (10 mM) of pH 7.4 was prepared. A portion (5 
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Figure 2.10. Estimation of the half life of compound 5 at physiological pH 7.4. 
The relative peak intensity of 5 was plotted against time and the data was fitted 
To a single exponential. The t
1/2
 was estimated to be 3.6 hours. 
ml) of this buffer was lyophilized and re-dissolved in deuterium oxide. This step was repeated 
thrice so as to ensure a complete H/D exchange. The buffer components were re-dissolved in 
deuterium oxide (5 ml). The hydrolysis experiment was carried out under pseudo first order 
reaction condition. A stock solution of 5, freshly made in deuterated DMSO was added to 
deuterated phosphate buffer (total volume 500 μl; net concentration of 5 at 2.5 mM) and NMR 
spectra were recorded after appropriate time intervals. The rate of hydrolysis was measured by 
comparing the integration values of initial and final compounds. The rate constant of hydrolysis 
was obtained by fitting the data to a single exponential decay curve (It=I0e
-k*t
) and the half was 





 The molecular modeling studies were performed on a Dell PowerEdge 6000 server 
operating on Red Hat Enterprise Linux ES release 4. The CH3CONHCysCONHCH3  peptide 
covalently attached to inhibitor 5 at the terminal aliphatic carbon was built with open oxirane 
ring in Builder module of Maestro 7.5 software and partial charges on each atoms were 
determined in Jaguar (Schrodinger Inc., New York, NY, USA) using density-functional  theory 
(DFT) calculation with B3LYP/6-31G* basis set. The coordinate file of cathepsin B (PDB id: 
2DC6) was downloaded and appropriately modified at pH 7.0 to include inhibitor 5 covalently 
linked to Cys29Sγ residue using Insight II software (Accelrys Inc., SanDiego CA, USA). The 
partial charges on the atoms of inhibitor were assigned from DFT calculations and the complex 
was soaked with a 15 Å spherical shell of water with Cys29Sγ as the center. The resulting 
complex was energy minimized (10,000 steps of Steepest Descent). A molecular dynamics run 
(100 ps) was then carried out on the energy-minimized complex using Consistent Valence 
Forcefield (CVFF) force field in Discover standalone program (Accelrys Inc., San Diego CA, 
USA). The trajectories from molecular dynamic run were saved every 2 ps and analyzed. During 
the energy minimation procedure and the molecular dynamics simulations, no constratins were 
imposed on 5-cathepsin B inhibitor complex. 
Cell culture:  
 All the cell culture reagents were purchased from Invitrogen (Carlsbad, CA). MDA-MB-
231 cells (American Type Culture Collection, Manassas, VA) were cultured on 10-cm plates 
(BD Falcon
TM
) at 37°C and 5% CO2 in Iscove’s Modified Dulbecco’s medium with L-glutamine 
(IMDM), 10% fetal bovine serum, and antibiotics (1% penicillin/streptomycin and 0.5 μg/ml 
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fungizone) as described earlier.
106
 Cells were passaged at 1:3 ratios every 3–4
 
days and 
subcultured by 0.25% trypsin-EDTA treatment. Cells were re-plated one day prior to experiment 
so that the cell density was 70-80% on the day of the experiment.  
Confocal microscopy:  
 For live-cell imaging, cells were seeded to Poly-D-lysine coated 35mm-glass bottom 
dishes (MatTek; Ashland, MA) and grown overnight in complete medium. Prior to imaging, cells 
were treated in 15 mM HEPES containing phenol-red (PR)-free complete medium. To reduce 
photo-bleaching, 0.6u of Oxyrase enzyme per ml (Oxyrase Inc.) was added to the PR-free 
medium containing 10 mM sodium-lactate, as previously described.
107
 Cells were incubated with 
either dimethylsufoxide (DMSO, 0.1% v/v) as vehicle control, or varying concentrations of 5 for 
20 minutes at 37
o
C, followed by an additional 10 minutes of incubation with the substrate Z-RR-
AMC (25 μM net) of 5. Images of cells were acquired using an inverted Leica TCS-SP5 confocal 
microscope (Leica; IL) by Plan apochromat 63x1.4 oil objective lens (numerical aperture 0.6-
1.4). An argon ion laser (25%) was used to generate an excitation at 488 nm, and pinholes were 
typically set to 1–1.5 Airy units. Results for every condition are the average over three 
independent experiments in each of which 8-10 cells were analyzed by Image J. 
Immunofluorescence:  
 Cells, grown on 35-mm glass coverslips in 6-well plate for 24 hrs, were treated with the 
vehicle (0.1% DMSO), or appropriate concentrations of cathepsin B inhibitor for 20 minutes at 
37
o
C. After treatment they were fixed in 3.7% PFA at room temperature for 10 minutes followed 
by 30 sec incubation in microtubule-stabilizing and cell-permeabilizing buffer (80 mM PIPES, 1 
mM MgCl2, 4 mM EGTA, 0.5% Triton-X100) at room temperature. The samples were then 
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washed thrice with phosphate-buffered saline (PBS) and incubated in immunoblocker (2% BSA, 
0.1% sodium azide) for 15 minutes at 37
o
C.  
 For immunostaining, cells were incubated overnight at 4
o
C with monoclonal mouse 
antibody E-cadherin (1:100) (Santa Cruz Biotechnology, Santa Cruz, CA) followed by 
incubation with secondary Alexa 594-conjugated donkey anti-mouse antibody (1:300) 




 DNA was stained with Hoechst 33342 (1 
mg/ml in PBS). Cells were mounted on clean glass slides using mounting media DABCO 
(Invitrogen). Samples were examined with a Plan-Neofluar 40x oil immersion objective lens 
(numerical aperture 0.75) using a Zeiss Axio Imager-M2 upright fluorescence microscope (Zeiss, 
Heidelberg, Germany). Results for every condition are the average of three independent 
experiments in each of which 28 cells were analyzed by ImageJ software.   
Western-blot analysis:  
 Cell lysate proteins were (50 µg) resolved by an 8% SDS-PAGE on Duracryl followed by 
electrophoretic transfer to 15x15 cm Immobilon-P (Millipore, Bedford, MA) nitrocellulose 
membranes. After blocking with 5% nonfat dry milk, membranes were incubated overnight at 
4
o
C with E-cadherin (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and DM1A-α-
tubulin mouse monoclonal antibody (1:5000) (Sigma-Aldrich, St. Louis, MO, USA), followed by 
incubation with peroxidase-conjugated secondary antibodies and chemiluminescence detection 
(Supersignal West Pico, Pierce). 
Cell Motility Assay:  
 The effect of inhibitor 5 on cell migratory behavior of MDA-MB-231 cells was evaluated 
by following a slight modification of an earlier published protocol.
109
 Thus MDA-MB-231 cells 
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were plated as concentric circles on a 10-well glass slide pre-coated with 1% BSA through a 10-
hole cell sedimentation manifold (CSM, Inc., Phoenix, AZ) followed by incubation at 37
 o
C and 
5% CO2. After removal of the manifold, cells were treated with control vehicle (0.05% DMSO) 
or appropriate concentrations of inhibitor 5, and incubated for 6 hours at 37
 o
C. Images were 
acquired by a digital camera (Moticam 2000) attached to an inverted Nikon Diaphot microscope 
both before (t0) and after inhibitory treatment (t6). Motility of cells was calculated by the change 
in total area (in square micrometers) by Image J software. Each reported value is the average of 






Serendipitous Discovery: Base-Catalyzed 













 A diverse group of important synthetic intermediates can be widely accessed through the 
chemistry of the aryl sulfonyl functional group
110
. Vinyl and allyl sulfones are important 
members of this class of compounds and are used as intermediates in a variety of organic 
transformations.
111
 For example, vinyl aryl sulfones have been successfully utilized to develop 
potent and selective inhibitory agents and activity-based probes of cysteine proteases.
112
  
Similarly, allyl aryl sulfones are convenient intermediates for synthesizing natural products, such 
as [(−)-erythrodiene], squalene, and coenzyme Q10.
113
  
Most synthetic methods for preparation of vinyl sulfones start with an alkene or 1-haloalkene 
derivative and involve multiple steps.
112a, 114
 One of the challenges in the synthesis of vinyl 
sulfones lies in the increased preference for ,  over ,  unsaturation. This often leads to 
isomeric mixtures of vinylic and allylic sulfones.
114a, 115
 Isomerically pure vinyl sulfones are 
easily synthesized in systems where ,  unsaturation is not possible.116 Most allylic sulfones are 
either prepared by treating vinylic sulfones with a base, or by a direct conversion of allylic 
alcohols or alkenes in the presence of a metal catalyst.
114a, 117
  Recently, the reaction of benzylic 




2.8 Discovery  
 In our effort to make vinyl sulfones as inhibitors of certain classes of therapeutically 
important enzymes, we followed established literature protocols for analogous reactions that 
involved the use of NaH with sulfonyl methylphosphonate
116, 119
. Thus, 1 was treated with 2-
phenylacetaldehyde in the presence of 2.0 equiv NaH at 0 °C resulting in a quantitative 
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conversion to allylic sulfone 9 without any trace of the desired vinylic sulfone 2 (Scheme 2.2). 
Even when we reduced the number of equivalents of NaH to 1.1 equiv, only allylic sulfone 9 
formed, again with no vinylic sulfone 2. The use of one equiv of NaH however yielded 
predominantly the vinylic sulfone 2 (4:1 vinylic:allylic mixture). Surprisingly, a further 
reduction of NaH (0.9 equiv) led to exclusive formation of vinylic sulfone 2, with no trace of the 
allylic sulfone 9. Importantly, all reactions went to completion within an hour, and any additional 
time of reaction did not affect either the regioselectivity of the products or their yield. This is an 
interesting finding since many of the literature methods involve significantly higher reaction 
times, and often give products with compromised regioselectivity
114
.  
 Our efforts to ascertain the structure of 2 was hampered by previously misreported 
spectral characteristics of this compound
114b, 120
. Therefore, a complete structural analysis by 









H scalar coupling between the olefinic 
protons was more than 15 Hz indicating a trans geometry for both compounds. The relative 






Scheme 2.2. Yield (calculated based on precursor aldehyde): 2 (81%), 3 (74%), 4 (71%), 5 
(66%), 6 (69%), 7 (75%), 8 (73%), 9 (94%), 10 (83%), 11 (81%), 12 (81%), 13 (84%), 14 




Figure 2.11. X-ray crystal structure of 2. ORTEP drawing with complete 
numbering of atoms, viewed approximately normal to the alkene plane. 
range correlation (HMBC) experiments (Appendix B). In addition, we also detected NOE 
between methylene protons and the ortho protons of the adjacent phenyl ring in 2 while a similar 
NOE was observed between one olefinic proton and the ortho protons of the adjacent phenyl ring 




C NMR peaks for 2 and 9 also established the 
characteristic spectral differences between the α, β unsaturation versus the β, γ unsaturation. For 
example, the methylene carbon in 9 experiences the –I effect of the sulfone and is 23 ppm 
downfield shifted compared to the methylene carbon in 2. The -R effect of the sulfone can be 
observed on the β olefinic carbon in 2 which is substantially downfield shifted and observed at 
145.42 ppm. The structure of 2 was also confirmed by X-ray crystallography (Figure 2.11).
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C NMR Chemical Shifts for vinyl phenyl sulfone, 2 and allyl phenyl sulfone, 
9.
a 
                    
 
13
C shifts (ppm) 
1
H shifts (ppm), J values in Hz 
 Compound 2 Compound 9 Compound 2 Compound 9 
1 131.53 60.51 6.26 (dt, 15.1, 1.7) 3.96 (dd, J=7.6, 1.2) 
2 145.42 115.12 7.16 (dt, 15.1, 6.5) 6.10 (dt, 15.8, 7.6) 
3 37.64 139.25 3.56 (dd, 6.5, 1.7) 6.36 (dt, 15.9, 1.2) 
a 140.5 138.30 - - 
b 127.64 128.55 7.86 (dd, 8.4, 1.4)
b 
7.88 (dd, 8.2, 1.3)
b
 
c 129.27 129.14 7.54 (tt, 7.5, 1.2)
b
 7.54 (tt, 7.5, 1.3)
b
 
d 133.34 133.84 7.62 (tt, 7.5, 1.3)
b
 7.64 (tt, 7.5, 1.3)
b
 
a’ 136.21 135.73 - - 















 Chemical shifts were measured relative to TMS at 20 
o
C on a 500 MHz NMR spectrometer. 
Solvent is CDCl3. To make comparison of shifts easier, the numbering of carbons is kept the 









These protons exhibit second-order splitting, the appearance of which may deviate by a small 
extent from the pattern mentioned here depending on the spectrometer frequency.  
After clearly establishing the structures of 2 and 9, we used six additional arylacetaldehyde 
substrates to probe the generality of the regio- and stereochemistry (Scheme 2.2). Thus, when a 
panel of 2-arylacetaldehydes, shown in scheme 1, were synthesized
122
 and subsequently treated 
with 1 using 0.9 and 1.1 equiv of NaH, the corresponding vinyl and allyl sulfones in high yields 
were obtained with exclusive E stereochemistry. To probe the importance of aryl substitution at 
the 2-position of acetaldehyde, the aliphatic aldehyde butanal was first examined. Thus, when 
butanal was allowed to react with 1 in the presence of 0.9 equiv of NaH, only the vinylic 
derivative 16 was observed with diminished stereoselectivity (Table 2.3). At 1.1 equivalents of 
NaH, a reaction of butanal with 1 gave allyl sulfone, but a substantial amount of vinyl sulfone 
was also present (Table 2.3). When 2.2 equiv. of NaH was used, the reaction gave allylic sulfone 
19 as the major product, again with diminished stereoselectivity. Table 2.3 lists the distribution 
of regioisomers with their E/Z ratios obtained for a panel of 2-alkylacetaldehydes. With 0.9 
equiv of NaH, exclusive formation of the vinylic sulfones was observed but again the 
corresponding allylic sulfones formed with diminished regio- and stereoselectivity when 1.1 
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equiv of NaH was used. These results, taken together, indicate that the base-controlled regio- and 
stereochemistry is sensitive to the nature of the α-substituent of the acetaldehyde.  
Table 2.3. Treatment of 1 with 2-alkylacetaldehydes under varying NaH concentrations. 
 
 Percent distribution of Vinyl and Allyl Isomers and their E/Z ratios
a  
R = With 0.9 equiv NaH With 1.1 equiv NaH 
-CH2CH3       100% 16 (5/1), 0% 19 58% 16 (13/1), 42% 19 (2/1) 
-CH(CH3)2       100% 17 (1/0), 0% 20  67% 17 (1/0), 33% 20 (1/1) 
-(CH2)4CH3       100% 18 (7:3), 0% 21  72% 18 (7/3), 28% 21 (1/1) 
a
Peaks corresponding to each isomer were integrated and normalized from the NMR spectrum of 




C NMR, and mass spectrometric characterization of 16 and 19 are 
included in the experimental section. Complete characterization of NMR peaks was not carried 




 To probe if a strong base such as NaH was essential for the observed regio- and 
stereoselectivity, we carried out the reactions of 1 with 2-phenylacetaldehyde and 1 with butanal 
in the presence of a weaker base, potassium tert-butoxide (1.1 equiv). In both cases, the 
exclusive regioselectivity was lost as the reaction with 2-phenylacetaldehyde yielded a 11:14 
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mixture of 9 and 2 while butanal gave a 17:3 mixture of 16 and 19. To assess if a base stronger 
than NaH could drive an exclusive conversion of butanal to allylic sulfones 19, a reaction of 1 
with butanal was carried out in the presence of 1.1 equiv of n-butyllithium. Surprisingly, the 
reaction yielded exclusively the vinyl sulfones 16, without any trace of corresponding allylic 
sulfones. This perhaps could be due to the compromised stability of n-butyllithium reagent in the 
reaction mixture under our experimental conditions (typically 0-10 °C, 1.5 hrs). Thus, it appears 
that an optimal basicity of NaH is required for this regio- and stereoselective transformation.  
Considering the results from Table 2.3, it is clear that aryl substitution at the γ position of 
the vinylic sulfones plays a crucial role for regio- and stereoselectivity, and only a catalytic 
amount of NaH is necessary for the formation of allyl sulfone from vinyl sulfone.  To gain 
further insight into the mechanism of this transformation, a computational analysis was 
undertaken [All calculations were carried out in vacuum using Spartan program. (Spartan '10, 
version 1.1.0, Wavefunction Inc., Irvine, CA, 2011). The structures of the E and Z isomers of 2, 
9, 16, and 19 were minimized using MM2 calculations. The minimized structures were then 
further subjected to DFT calculations using B3LYP/6-311G* basis set to obtain the equilibrium 
geometries and total energies. From the energy-minimized structures of 2 and 16, one of the 





 as well as total energy (ΔE) by DFT methods showed that allylic sulfones 9 and 
19E were thermodynamically more stable than their corresponding vinylic sulfones 2 and 16E 
by a comparable amount [ΔΔH
0
f favors 9 and 19E by  -13.1 kJ/mol and -14.9 kJ/mol 
respectively, and ΔE favors 9 and 19E by -20.4 kJ/mol and -24.1 kJ/mol respectively]. The 
energy-minimized geometry for the sulfones as well as the ΔE value for the conversion of 2 to 9 
agrees closely with the estimated values reported by Lee et al.
125
. To understand why only 
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Scheme 2.3. Proposed mechanism of the formation of allylic sulfone 9 when catalytic 
excess of sodium hydride is used. 
vinylic sulfone 2 would convert easily to allylic sulfone 9 with catalytic NaH but not the 
vinylic
75
sulfone 16, we compared the differences between the neutral sulfones and the anions 
obtained after proton abstraction to approximate the energy barrier for this conversion. DFT 
calculations at the B3LYP/6-311G* level showed that the difference is lower by 41.3 kJ/mol for 
2 compared to 16E. It can be inferred that the resonance stabilization of the resulting negative 
charge by the aromatic ring (23 – Scheme 2.3) plays a dominant role in the ease with which the 
allylic sulfone forms. Based on our experimental observation and computational analysis, a 
plausible mechanism for the quantitative conversion of 1 to 2 and 9 is proposed. The reaction 
proceeds through a cyclic Wittig intermediate 22 which readily breaks down to yield the vinylic 
sulfone 2
126
. When a catalytic excess of base is present, an acidic proton is abstracted from 2 to 
form a resonance-stabilized carbanion 23. This carbanion acts as a base to abstract another 
proton from 1 to form the thermodynamically stable product 9, thus regenerating carbanion 23 
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Scheme 2.4. Exclusive formation of allyl sulfone under varying base  
equivalent. 
which can subsequently turn over another substrate molecule 2. Catalytic participation of NaH 
has been observed previously.
127
 
 Having established the effect of conjugation from one phenyl moiety and to gain further 
support for our postulated mechanism, we hypothesized that 2,2-diphenylacetaldehyde will form 
the allyl sulfone even more favorably. We therefore synthesized 2,2-diphenylacetaldehyde
128
 and 
carried out a reaction with 1 using 0.9 equiv NaH. Not surprisingly, the reaction exclusively gave 
the allylic sulfones 24 (Scheme 2.4), a compound that has been previously prepared by other 
methods.
129
 When this reaction was repeated with 0.5 equiv of NaH, it still resulted in a 
quantitative conversion of the 2,2-diphenyl-acetaldehyde to 24 (50% overall yield) with no trace 
of the vinyl sulfone. Indeed the ΔE calculations by DFT methods show that formation of 24 is 
favored by 35.9 kJ/mol over its corresponding vinylic isomer (i.e. about twice the amount 
calculated for 9). Both experimental results and theoretical calculations confirm that an extended 






2.9 Concluding Remarks  
 In conclusion, we have described a convenient general route to synthesize vinylic and 
allylic sulfones that contain an aromatic group on the γ-carbon of the sulfones. The reactions 
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described here proceed in just 1 hr time, do not require any metal catalyst, and yield exclusively 
a single product with high regio- and stereoselectivity. Importantly, this can be achieved simply 
by changing the amount of NaH used in the reaction mixture. Thus, while a catalytic excess of 
NaH (1.1 equiv) produces the allylic sulfones in quantitative yield upon reaction of 1 with 2-






















C NMR and 
1
H spectra were recorded on a Brucker DPX 400 MHz FT NMR 
with automatic sample changer. Chemical shifts (δ) are reported in parts per million (ppm) and 
referenced to CDCl3 (7.26 ppm for 
1
H and 77.0 ppm for 
13
C), (CD3)2CO (2.05 ppm for 
1
H and 
29.9, 206.7 for 
13
C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are 
abbreviated as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), 
and multiplet (m). 
Synthesis  
 Typical procedure for synthesis of 2-8: A solution of diethyl 
((phenylsulfonyl)methyl)phosphonate (500 mg, 1.7 mmol, 1 equiv) in dry tetrahydrofuran (2 
mL) was added dropwise to a stirring suspension of sodium hydride (39 mg, 1.53 mmol, 0.9 
equiv) in dry tetrahydrofuran (5 mL) at 0 °C under inert condition. After 30 minutes a solution of 
α-substituted acetaldehyde (1.7 mmol, 1.0 equiv) in dry tetrahydrofuran (3 mL) was added to the 
reaction mixture. Stirring was continued for an hour. The reaction was quenched by addition of 5 
mL of sodium bisulfate (5 wt% solution). The solution was concentrated under vacuum, diluted 
with water (10 mL) and extracted with ethylacetate (3 x 5 mL). The combined organic extracts 
were washed with saturated aqueous sodium bicarbonate and brine, dried over sodium sulfate, 
filtered and concentrated under vacuum. Purification by flash column chromatography (silica 
gel; 97:3 hexane:ethylacetate) provided the desired product.  
Compounds 9-15 were synthesized by following the same protocol used in the synthesis of 2-8 
except that 1.1 equiv (44.9 mg, 1.87 mmol) of NaH was used. For the synthsis of 24, E and Z 
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isomers of 16-21, appropriate amount of NaH was utilized (see Table 2). The characterizations of 
compounds are as follows:  





NMR aasignments]. LRMS [ESI-MS +ve] calculated for (C15H14O2S+Na): 281.1, observed: 
281.3. 
(E)-4-(3-(phenylsulfonyl)allyl)-1,1'-biphenyl (3). Yield: 74%. 
1
H NMR (400 MHz, (CDCl3) δ 
ppm: 3.60 (d, J = 6.6 Hz, 2H), 6.30 (d, J = 15.2 Hz, 1H), 7.14-7.66 (m, 13H), 7.88(m, 2H). 
13
C 
NMR (100 MHz, (CDCl3) δ ppm: 37.27, 127.04, 127.39, 127.61, 127.67, 128.82, 129.28, 
129.29, 131.64, 133.37, 135.21, 140.12, 140.47, 140.58, 145.30. LRMS [ESI-MS +ve] calculated 
for (C19H16O2S+Na): 357.1, observed: 357.2 
(E)-1-(3-(phenylsulfonyl)allyl)naphthalene (4). Yield: 71%.  
1
H NMR (500 MHz, (CD3)2CO) δ 
ppm: 4.14 (d, J = 6.4 Hz, 2H), 6.51(d, J =15.1 Hz, 1H), 7.20-8.09 (m, 13H). 
13
C NMR (125 
MHz, (CDCl3) δ ppm: 34.36, 123.77, 125.71, 125.85, 126.27, 127.10, 127.35, 127.76, 128.76, 
129.35, 131.68, 131.97, 133.28, 133.53, 134.07, 141.22, 145.47.  LRMS [ESI-MS +ve] 
calculated for (C19H16O2S+Na): 331.1, observed: 331.2 
(E)-1-methyl-2-(3-(phenylsulfonyl)allyl)benzene (5). Yield: 66%. 
1
H NMR (500 MHz, CDCl3) δ 
ppm: 2.20 (s, 3H), 3.56 (dd, J = 6.2 and 1.4 Hz, 2H), 6.13 (dt, J = 15.2 and 1.4 Hz, 1H), 7.05 (d, J 
= 6.9 Hz, 1H), 7.16 (m, 4H), 7.53 (t, J =7.6 Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.85 (d, J = 7.6 Hz, 
2H). 
13
C NMR (100 MHz, (CDCl3) δ ppm: 19.3, 35.4, 126.5, 127.4, 127.6, 129.2, 129.6, 130.6, 
131.5, 133.3, 134.6, 136.3, 140.6, 145.1. LRMS [ESI-MS +ve] calculated for (C16H16O2S+Na): 
295.1 Observed: 295.0Calculated Mass for (C16H16O2S+Na): 295.1 Observed: 295.0  
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(E)-1-chloro-2-(3-(phenylsulfonyl)allyl)benzene (6). Yield: 69%.  
1
H NMR (500 MHz, CDCl3) δ 
ppm: 3.63 (dd, J = 6.3 and 1.4 Hz, 2H), 6.23 (tt, J = 15.0 and 1.4 Hz, 1H), 7.13 (dt, J = 15.0 and 
6.3 Hz, 1H), 7.17 (m, 1H), 7.22 (m, 2H) 7.37 (m, 1H), 7.53 (t, J =7.7 Hz, 2H), 7.62 (t, J = 7.7 Hz, 
1H), 7.86 (d, J = 7.7 Hz, 2H). 
13
C NMR (100 MHz, (CDCl3) δ ppm: 35.4, 127.3, 127.6, 128.8, 
129.3, 129.9, 130.8, 131.9, 133.3, 134.1, 134.3, 140.4, 143.7. LRMS [ESI-MS +ve] calculated 
for (C15H13ClO2S): 315.0 Observed: 315.0  
(E)-1-methyl-4-(3-(phenylsulfonyl)allyl)benzene (7). Yield: 75%.  
1
H NMR (400 MHz, CDCl3) 
δ ppm: 2.32 (s, 3H), 3.51 (dd, J = 6.6 and 1.8 Hz, 2H), 6.25 (dt, J = 15.0 and 1.8 Hz, 1H), 7.00 
(d, J = 8.0 Hz, 2H) 7.11 (d, J = 8.0 Hz, 2H), 7.13 (dt, J = 15.0 and 6.6 Hz, 1H), 7.52 (tt, J = 7.6 
and 1.4 Hz, 2H), 7.61, (tt, 7.6 and 1.4 Hz, 1H), 7.86 (dd, J = 7.6 and 1.4 Hz, 2H). 
13
C NMR (100 
MHz, (CDCl3) δ ppm: 21.0, 37.2, 127.6, 128.7, 129.3, 129.6, 131.3, 133.1,133.3, 136.7, 140.6, 
145.8. LRMS [ESI-MS +ve] calculated for (C16H16O2S + Na): 295.1 Observed: 295.0 
(E)-1-methoxy-4-(3-(phenylsulfonyl)allyl)benzene (8). Yield: 73%.  
1
H NMR (400 MHz, 
CDCl3) δ ppm: 3.50 (dd, J = 6.6 and 1.3 Hz, 2H), 3.79 (s, 3H), 6.23 (dt, J = 14.9 and 1.3 Hz, 1H), 
6.84 (d, J = 8.6 Hz, 2H) 7.03 (d, J = 8.6 Hz, 2H), 7.13 (dt, J = 14.9 and 6.6 Hz, 1H), 7.53 (tt, J = 
7.6 and 1.3 Hz, 2H), 7.61, (tt, 7.6 and 1.3 Hz, 1H), 7.86 (dd, J = 7.6 and 1.3 Hz, 2H). 
13
C NMR 
(100 MHz, (CDCl3) δ ppm: 36.8, 55.3, 114.3, 127.6, 128.1, 129.3, 129.9, 131.2, 133.3, 140.6, 
145.9, 158.7. LRMS [ESI-MS +ve] calculated for (C16H16O3S+Na): 311.1 Observed: 311.0  




C NMR assignments]. 
LRMS [ESI-MS +ve] calculated for (C15H14O2S+Na): 281.1, observed: 281.2 
(E)-4-(3-(phenylsulfonyl)prop-1-en-1-yl)-1,1'-biphenyl (10). Yield: 83%.  
1
H NMR (500 MHz, 
(CD3)2CO) δ ppm: 4.12 (d, J = 7.6 Hz, 2H), 6.22 (m, 1H), 6.53 (d, J =15.9 Hz, 1H), 7.32-7.51 
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(m, 5H), 7.59-7.77 (m, 7H), 7.92 (d, J = 7.4 Hz, 2H). 
13
C NMR (125 MHz, (CD3)2CO) δ ppm: 
59.66, 116.24, 126.69, 127.09, 127.10, 127.51, 128.37, 128.90, 129.14, 133.67, 135.32, 137.96, 
139.30, 140.24, 140.77. LRMS [ESI-MS +ve] calculated for (C19H16O2S+Na): 357.1, observed: 
357.2 
(E)-1-(3-(phenylsulfonyl)prop-1-en-1-yl)naphthalene (11). Yield: 81%. 
1
H NMR (400 MHz, 
(CDCl3) δ ppm: 4.09 (dd, J = 7.65, 1.0 Hz, 2H), 6.13 (m, 1H), 7.08 (d, J = 15.6 Hz, 1H), 7.38-
7.96 (m, 12H). 
13
C NMR (100 MHz, (CDCl3) δ ppm: 60.69, 118.51, 123.50, 124.30, 125.57, 
125.99, 126.26, 128.56, 128.68, 128.86, 129.21, 130.84, 133.46, 133.53, 133.80, 136.98, 138.28. 
LRMS [ESI-MS +ve] calculated for (C19H16O2S+Na): 331.1, observed: 331.2 
(E)-1-methyl-2-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (12). Yield: 69%. 
1
H NMR (500 
MHz, (CDCl3) δ ppm: 2.13 (s, 3H), 3.98 (d, J = 7.6 Hz, 2H), 5.98(dt, J =15.5, 7.6 Hz, 1H), 6.56 
(d, J = 15.5 Hz, 1H), 7.10 (dd, J = 7.4, 2.0 Hz, 1H), 7.16 (td, J = 7.4, 2.0 Hz, 1H), 7.19 (td, J = 
7.4, 2.0 Hz, 1H), 7.34 (dd, J = 7.4, 2.0 Hz, 1H), 7.54 (tt, J = 7.5, 1.3 Hz, 2H), 7.64 (tt, J = 7.5, 1.3 
Hz, 1H), 7.90 (dd, J = 7.5, 1.3 Hz, 2H). 
13
C NMR (100 MHz, (CDCl3) δ ppm: 19.5, 60.7, 116.6, 
125.9, 126.2, 128.4, 128.6, 129.1, 130.3, 133.8, 134.9, 135.6, 137.3, 138.4. LRMS [ESI-MS +ve] 
calculated for (C16H16O2S+Na): 295.1, observed: 295.0 
(E)-1-chloro-2-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (13). Yield: 84%. 
1
H NMR (400 
MHz, (CDCl3) δ ppm: 4.00 (d, J = 7.6 Hz, 2H), 6.12 (tt, J =15.7, 7.6 Hz, 1H), 6.71 (d, J = 15.7 
Hz, 1H), 7.21 (m, 2H), 7.31 (m, 1H), 7.46 (m, 1H), 7.55 (tt, J = 7.4, 1.4 Hz, 2H), 7.65 (tt, J = 7.4, 
1.4 Hz, 1H), 7.89 (dd, J = 7.4, 1.4 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ ppm: 60.5, 118.2, 
127.0, 127.1, 128.5, 129.2, 129.5, 129.7, 133.2, 133.8, 133.9, 135.4, 138.2. LRMS [ESI-MS +ve] 
calculated for (C15H13ClO2S): 315.0 Observed: 315.0 
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(E)-1-methyl-4-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (14). Yield: 82%. 
1
H NMR (400 
MHz, CDCl3) δ ppm: 2.34 (s, 3H), 3.94 (d, J = 7.6 Hz, 2H), 6.05 (dt, J = 15.6 and 7.6 Hz, 1H), 
6.32 (d, J = 15.6 Hz and 1H) 7.11 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.53 (tt, J = 7.6 
and 1.4 Hz, 2H), 7.63 (tt, 7.6 and 1.4 Hz, 1H), 7.88 (dd, J = 7.6 and 1.4 Hz, 2H). 
13
C NMR (100 
MHz, (CDCl3) δ ppm: 21.3, 60.6, 114.0, 126.6, 128.6, 129.1, 129.4, 133.0, 133.7, 138.4, 138.6, 
139.2. Calculated Mass for (C16H16O2S+Na): 295.1 Observed: 295.0 
(E)-1-methoxy-4-(3-(phenylsulfonyl)prop-1-en-1-yl)benzene (15). Yield: 85%. 
1
H NMR (500 
MHz, CDCl3) δ ppm: 3.81 (s, 3H), 3.93 (d, J = 7.7 Hz, 2H), 5.96 (tt, J =15.6, 7.7 Hz, 1H), 6.31 
(d, J = 15.6 Hz, 1H), 6.84 (dd, J = 8.7 Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.54 (t, J = 7.7 Hz, 2H), 
7.64 (t, J = 7.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ ppm: 55.3, 
60.6, 112.6, 114.1, 127.9, 128.5, 128.6, 129.1, 133.7, 138.5, 138.7, 159.9. LRMS [ESI-MS +ve] 
calculated for (C16H16O3S+Na): 311.1 Observed: 311.0 
(E)-(pent-1-en-1-ylsulfonyl)benzene(16E). 
1
H NMR (500 MHz, CDCl3) δ ppm: 0.92 (m, 3H), 
1.50 (m, 2H), 2.23 (m, 2H), 6.33 (d, J = 15.0 Hz, 1H), 7.00 (m, 1H) 7.54 (m, 3H), 7.87 (m, 2H). 
13
C NMR (125 MHz, CDCl3) δ ppm: 13.6, 20.9, 33.4, 127.5, 129.3, 130.4, 133.3, 140.7, 147.1. 
LRMS [ESI-MS +ve] calculated for (C11H14O2S+Na): 233.1, observed: 233.3.  
(Z)-(pent-1-en-1-ylsulfonyl)benzene (16Z). 
1
H NMR (500 MHz, CDCl3) δ ppm: 0.92 (m, 3H), 
1.50 (m, 2H), 2.64 (m, 2H), 6.33 (m, 2H), 7.54 (m, 3H), 7.92 (m, 2H). 
13
C NMR (125 MHz, 
CDCl3) δ ppm: 13.7, 21.9, 29.6, 127.2, 129.3, 130.5, 133.4, 141.8, 147.5. LRMS [ESI-MS +ve] 
calculated for (C11H14O2S+Na): 233.1, observed: 233.2.    
(E)-(pent-2-en-1-ylsulfonyl)benzene(19E). 
1
H NMR (500 MHz, CD3OD) δ ppm: 0.88 (t, J = 
7.52Hz, 3H), 1.98 (m, 2H), 3.87 (d, J = 7.31 Hz, 2H), 5.37(m, 1H), 5.56 (m, 1H), 7.71 (m, 2H), 
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7.71 (m, 1H), 7.86(m, 2H). 
13
C NMR (125 MHz, MeOD-D4) δ ppm: 12.0, 25.2, 59.1, 115.2, 




H NMR (500 MHz, CD3OD) δ ppm: 0.71 (t, J = 
7.55 Hz, 3H), 1.77 (m, 2H), 3.98 (d, J = 8.01, 2H), 5.37 (m, 1H), 5.70 (m, 1H), 7.62 (m, 2H), 
7.71 (m, 1H), 7.89 (m, 2H). 
13
C NMR (125 MHz, MeOD-D4) δ ppm: 12.3, 20.1, 54.2, 114.5, 




H NMR (500 MHz, CDCl3) δ ppm: 3.93 
(d, J = 7.9 Hz, 2H), 6.15 (t, J = 7.9 Hz, 1H), 6.67 (d, J = 7.6 Hz, 2H), 7.16 (m, 2H), 7.23 (t, J = 
7.6 Hz, 2H), 7.27 (m, 4H), 7.51 (t, J = 7.6 Hz, 2H), 7.64 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 7.6 Hz, 
2H). 
13
C NMR (100 MHz, CDCl3) δ ppm: 57.5, 114.0, 127.4, 127.8, 128.2, 128.3, 128.4, 128.5, 
129.1, 129.2, 130.1, 133.7, 137.7, 138.5, 140.7, 149.7. LRMS [ESI-MS +ve] calculated for 
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 Cathepsin L is a prominent member of cysteine cathepsin family of enzymes whose 
aberrant function has been linked to metastatic cancer
83
. Cathepsin L promotes metastatic 
behavior by efficiently degrading and hydrolyzing various components of the extracellular 
matrix (ECM), such as laminin, fibronectin, and collagen. Numerous studies strongly indicate 
that cathepsin L activates signaling pathways that drive invasion in metastatic cancer
45b, 131
. Its 
inhibition in invasive cancer is considered an attractive strategy for anti-cancer drug 
development. 
    Despite the linkage of cathepsin L to metastatic cancer, its functions in appropriate 
cellular contexts also remain largely unknown. Although it is generally believed that in normal 
cells cathepsin L is endosomal or lysosomal, nuclear and cytosolic roles have also recently 
emerged in other cells
37, 132
. In addition, numerous contradictory roles of cathepsin L have been 
reported. For example, in glioblastoma nuclear cathepsin L activity is involved in regulating the 
activity of transcription factors in a manner that promotes aberrant proliferation
133
. In contrast, a 
pro-apoptotic role was attributed to cytosolic cathepsin L in human glioma cells
134
. In the context 
of bone tissues, cathepsin L seems to be involved in both bone growth
135
 and bone loss 
processes
136
. Such examples suggest that the underlying role of cathepsin L depends on its 
activation level in distinct cell-types and its specific microenvironment. Determination of the 
cellular level of activated cathepsin L would require a cell-active, potent and selective small 
molecule probe. In recent years, activity-based probes have emerged as powerful tools for such 
tasks
137
. Acquisition of a suitable activity-based cathepsin L probe however requires that first a 
small molecule inhibitor be developed that (a) is cell-permeable, (b) inhibits cathepsin L activity 
potently and selectively, (c) utilizes a covalent irreversible chemistry for inhibition, and (d) is 
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non-basic in nature. The property of being non-basic is especially important for homogenous 
distribution of probe in cell or else an undesired accumulation (and thus non-selective inhibition 
of other cysteine cathepsins) will occur in the acidic environment of the lysosome
138
. While 
several potent and reversible modulators of cathepsin L activity exist, only a few irreversible 
inactivating agents have been reported so far; none of which are suitable for development of a 
cell-active activity-based cathepsin L probe. In this study, using a hybrid-design approach, the 
development of a highly potent, selective, non-basic, and active-site directed irreversible 
inhibitor (KD-1, Figure 3.1) of cathepsin L activity is reported.  
 
3.2 Rationale 
 The active site architecture of cathepsin L includes substrate binding cavities made of 
both non-prime and prime site pockets, arranged on two sides of the scissile amide bond
27
. The 
molecular framework of a cathepsin L-specific inhibitor was conceptualized so that the 
functional groups occupied both the regular non-prime site (i.e. S1, S2, S3) and the prime site 
(S′) binding pockets. Earlier studies involving x-ray crystallography indicated that the S′ pocket 
of cathepsin L could provide a strategic site for designing a selective and potent inhibitor
139
. A 
visual analysis of a covalent and reversible inhibitor, Z-Phe-Tyr-(O-tert Bu)-C(O)CHO, bound to 
cathepsin L indicated that a non-polar cluster from the S′ pocket, involving Trp189, Leu144, 
Ala138, and Gly139 residues, formed critically important binding interactions with the tert-butyl 
group.
139b
 In another related study, it was noted that an aromatic moiety suitably placed could 
perhaps form more effective inhibitory interactions with the S′ residues of cathepsin L.
140
 Thus, 
we sought to first screen for a ligand that would contain an electrophilic warhead and a 
functionalized aromatic group suitable for interacting with the prime site residues. Although 
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Figure 3.1. A hybrid-design approach in the development of a highly potent time-dependent 
inhibitor (KD-1) of human cathepsin L. To generate KD-1, a competitive inhibitor CBZ-Phe- 
Leu-CONH
2
 of modest potency (K
i
=14 µM), known to target S1, S2, and S3 pockets of 
cathepsin L, is conjugated to a prime site (S’)-targeting inhibitory ligand 1 at its C-terminal. 
vinylsulfones have been utilized as an electrophilic warhead
57, 141
, the vinylsulfonate ester moiety 
has not yet been explored for the development of a covalent and irreversible inhibitor of 
cathepsin L. This was perhaps surprising since it was carefully noted that vinylsulfonate ester 
moiety displays a far superior reactivity as a Michael acceptor than vinyl sulfones (and 
sulfonamides)
142
. In addition, we surmised that an additional S-O bond present in vinylsulfonate 
(but not in vinylsulfone) could place the functionalized aryl group into the S′ pocket for optimal 
interaction. To test this hypothesis for cathepsin L inhibition, the inhibitory potency of phenyl 
vinylsulfonate and phenyl vinylsulfone towards cathepsin L was determined. As anticipated, 
phenyl vinylsulfonate exhibited 3-fold better potency than phenyl vinylsulfone under identical 
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experimental conditions (data not shown). This finding strengthened the possibility that an 
effective S′-targeting ligand could be constructed. Thus a focused library of aryl vinylsulfonate 
ester compounds was synthesized and screened against cathepsin L (see experimental section). 
This screen identified 4-bromophenyl vinylsulfonate ester (Figure 3.1, Compound 1) as the most 
effective lead aryl vinylsulfonate ligand. 
 Torkar et al.
58
 recently reported Cbz-Phe-Leu-CONH2 (Figure 3.1A) as a modest 
inhibitor (Ki = 14 µM) of cathepsin L. This compound is non-basic and inhibits cathepsin L 
activity by presumably occupying the non-prime pockets (i.e. S1, S2, and S3). We hypothesized 
that a hybrid design that incorporated the key features of 1 and Cbz-Phe-Leu-CONH2 could 
render a highly potent and selective inhibitor of cathepsin L. Thus KD-1 was conceived (Figure 
3.1) and synthesized. 
 
3.3 Chemistry 
KD-1 was synthesized according to scheme 3.1. Oxidation of N-Boc-L-Leucinol lead to 
corresponding aldehyde which was utilized for the next step without any further purification
143
. 
Wittig intermediate (II) was synthesized from ethyl methanesulfonate by treating with 
butyllithium followed by addition of diethyl chlorophosphate in anhydrous THF under inert 
condition
144
. Treatment of intermediate II with sodium hydride followed by addition of N-Boc-
L-Leucinal (II) in anhydrous THF under inert condition yielded Boc-protected leucine 
vinylsulfonates (III). Deprotection of Boc group was carried out by treating intermediate III with 
25% TFA in DCM. The free amine thus obtained was coupled to commercially available Cbz-
protected phenylalanine to generate intermediate IV. Treatment of IV with tetrabutyl ammonium 
iodide in acetone led to sulfonate salt which was utilized for the next step without any further 
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Scheme 3.1: Synthetic route utilized in the development of cathepsin L inhibitor, KD-1.  
purification. The sulfonate salt, thus obtained, was converted to sulfonyl chloride by treating 
with sulfuryl chloride in presence of triphenylphosphine. The intermediate sulfonyl chloride was 
treated with 4-bromo phenol in presence of triethyl amine to obtain final compound KD-1. 
 
3.4 Results and Discussion 
 To get an estimate of potency, an experiment was performed to obtain the IC50 value. As 
anticipated, a highly potent inhibition was observed (IC50 = 3.6 ± 0.1 nM). Since the IC50 value is 
not an accurate indicator of potency of a time-dependent inhibitor, a dose-dependent experiment 
was performed at various inhibitor concentrations and the progress curves were recorded under 
pseudo-first order conditions (i.e. [KD-1]>>[Cat. L]) (Figure 3.2). Analysis of the progress 
curves
58
 revealed near diffusion-controlled inactivation kinetics (second order inactivation rate 






). The mode of inhibition was irreversible in nature because 
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Figure 3.2. Time-dependent inhibition of human cathepsin L by KD-1. Progress 
curves for cathepsin L-catalyzed hydrolysis of fluorescent substrate, Z-Phe-Arg-(7-
amino-4-methylcoumarin, in the absence and presence of appropriate concentration of 
KD-1. 
enzyme activity could not be recovered, even after a very large dilution of the inactivated 
reaction mixture (data not shown). 
 The selectivity of KD-1 towards cathepsin L enzyme was assessed next. To demonstrate 
this, a panel of recombinant proteases and phosphatases were evaluated for their inhibition using 
steady-state inhibition assays. This panel of enzymes included cysteine cathepsins, an aspartyl 
cathepsin, a serine cathepsin, a cysteine containing enzyme PTP, and a serine protease. The 
second order inactivation rate constants were thus determined by performing inactivation 
kinetics under a pseudo-first order condition, as described before
94
 (Table 3.1). In the panel of 
enzymes tested, KD-1 displayed a remarkable selectivity towards cathepsin L.  
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Table 3.1. Second order enzyme inactivation rate constants (kinact) of cathepsin L inhibitor KD-1 
against a panel of closely-related enzymes. 




)        RSF 
Cysteine Cathepsins                     Cathepsin L             4.3x10
6            
1 
                                                      Cathepsin K            4.4x10
4            
100 
                                                      Cathepsin B             96                 44,000 
                                                      Cathepsin S             3.5x10
5            
13 
                                                      Cathepsin H             NI                 NA
**
 
Aspartyl Cathepsin                       Cathepsin D             NI




Serine Cathepsin                             Cathepsin G          NI




Protein Tyrosine Phosphatase          hptp1b                 NI
*                    
NA
**
                    
                                                       
 
Serine Protease                                Trypsin                 NI
*                    
NA
**
                                     
Relative Selectivity Factor (RSF) = kinact (Cathepsin L) / kinact (Other enzyme); NI
*
 = No 
Inhibition at 0.1 mM  of KD-1 in 1 h; NA
**
 = Not Applicable. 
While a 13- and 100-fold selectivity was observed against most closely homologous cysteine 
cathepsins S and K respectively, a very high selectivity (44,000 fold) was observed against 
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cysteine cathepsin B. Furthermore, no reactivity was observed against other panel of enzymes 
(e.g. aspartyl cathepsin D, serine cathepsin G, and a low pKa cysteine containing enzyme 
hPTP1B, and serine protease trypsin). A remarkable selectivity profile observed for KD-1 in 
these experiments is noteworthy and should bode well for biological applications.  
 The ability of KD-1 to decrease the activity of cathepsin L towards collagen type I, a 
physiological substrate of cathepsin L, was investigated next
145
. As expected, KD-1 protected the 
degradation of human collagen type I by cathepsin L in vitro (Figure 3.2A). To further 
demonstrate that KD-1 was cell permeable and therefore suitable for use in biological contexts, 
an experiment involving metastatic breast cancer MDA-MB-231 cells was performed. This cell 
line is known to overexpress cathepsin L
146
, thereby promoting invasion. A cell-permeable 
fluorescent substrate of cathepsin L, Z-Phe-Arg-(7-amino-4-methylcoumarin, was utilized to 
assess the intracellular inhibitory efficacy of KD-1. A near complete loss of intracellular 
substrate turnover (as indicated by loss of green fluorescence) was evident in KD-1-treated cells, 
compared to control (Figure 3.2B). This experiment demonstrated that KD-1 was indeed cell 
permeable and was able to successfully block cathepsin L activity in intact cells. To the best of 
our knowledge this is the first example where an inhibitor developed against cathepsin L is (i) 
highly potent and selective (ii) non-basic (iii) hydrolytically stable, and most importantly (iv) cell 
active. Such desirable traits are anticipated to lend themselves well in delineating precise roles of 
cathepsin L biology in specific tissue-types, and the development of a selective activity-based 
cathepsin L probe. 
 Finally, the functional effect of KD-1 on migratory behavior of highly metastatic MDA-
MB-231 cells was investigated using a wound-healing assay. The metastatic cells are highly 
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Control:DMSO KD-1(750 nM) 
A B 
Figure 3.3: [A] Inhibitor KD-1 protects a physiological substrate of cathepsin L, 
 human collagen type I, from proteolytic degradation in vitro. The α, β, and γ bands  
of collagen I are shown by blue arrows (left) [B] Effect of KD-1 on cathepsin L  
activity in a metastatic breast cancer cell line. MDA-MB-231 cells were incubated  
with (a) vehicle (DMSO 0.05%), and (b) KD-1 (750 nM) overnight (22 hrs).  
Intracellular inhibition of cathepsin L activity was assessed by exposing the cell to a 
 cell-permeable fluorogenic substrate, Z-Phe-Arg-(7-amino-4-methylcoumarin) 
 (2 minutes). The signal intensity (green) that emergesfrom the enzymatic turnover 
 of the fluorophore substrate (white arrow) is lost when inhibitor KD-1 is present.  
This experiment demonstrates that KD-1 is cell permeable, and is inhibiting 
 intracellular cathepsin L activity in these cells. The results are representative of 3 
independent experiments. Scale bar = 25 μm. 
Collagen Type I     +        +      +      +      + 
target of overabundant cathepsin L
43
. Most cancer cells lose E-cadherin function as they become 
migratory, and hence metastatic. When MDA-MB-231 cells were treated with KD-1 (compared 
with DMSO-treated control cells) and the wound-healing assay was initiated, it was observed 
that cell motility decreased in KD-1-treated cells, compared to control (Figure 3.4). This result is 
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consistent with cellular inhibition of cathepsin L by KD-1 since an enhanced integrity of cell-cell 
junctions is expected in these cells due to maintenance of appropriate levels of E-cadherin. 
Further experiments are currently being planned to systematically investigate the effect of KD-1 
on other invasive cancer cell types. 
3.5 Conclusions 
 Using a hybrid-design approach and employing a vinylsulfonate ester functionality, a 
highly potent and selective cathepsin L inhibitory agent KD-1 has been developed. KD-1 
successfully blocks intracellular cathepsin L activity in intact cells, and possesses anti-migratory 
potential. It is anticipated that KD-1 will find extensive applications in probing the 
undocumented roles of cathepsin L in diverse cellular microenvironments and human diseases.
147





t = 0 
hr. 
t = 22 
hrs. 
KD-1(750 nM) A 
* 













Figure 3.4. [A] KD-1 reduces migratory potential of highly metastatic MDA-MB-231 
 Breast cancer cells, as assessed by the wound healing assays. MDA-MB-231 cells were 
grown overnight in a 6-well plastic dish before treating with DMSO (control, 0.05%) or KD-1  
(750 nM). After creating the wounds by drawing a pipet across a confluent field of cells, 
 images were acquired at 0 h and 22 h. Representative images of three independent  
experiments are shown here. The dotted yellow lines indicate the edge of the wound at time 
zero, and the height of the yellow arrows are indicative of wound width. [B] The wound  
closure, a direct measurement of cell migratory potential, was calculated using the following  






] × 100%, where A
0 
is the area of the wound  
measured immediately after the scratch, and A
22 
is the area of the wound after 22 h. 
 The figure represents a statistical analysis from 3 independent experiments using the 
 unpaired Student’s t test (*, p<0.0001). The data were evaluated as the mean +1 standard 





3.6.1 Synthesis  
General:  
1
H NMR spectra were recorded at either 400 or 500 MHz using CDCl3 or DMSO 
as the solvent. 
13
C NMR spectra were recorded at either 125 or 100 MHz using CDCl3 or DMSO 
as the solvent. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to 
CDCl3 (7.26 ppm for 
1
H and 77.0 ppm for 
13
C), DMSO (2.50 ppm for 
1
H and 39.5 ppm for 
13
C). 
Coupling constants (J) are reported in Hertz (Hz) and multiplicities are abbreviated as singlet (s), 
doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), and multiplet (m). The 
mass spectra were acquired using a 6520 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) 
LC/MS (Agilent Technologies, Santa Clara, CA, USA). 4-ethynylbenzyl alcohol was purchased 
from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA).  O-(1H-6-Chlorobenzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased from peptide 
international (Louisville, Kentucky, USA). All anhydrous solvents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other materials were purchased from Fisher Scientific Inc. 
(Pittsburgh, PA, USA). 
Synthesis of library of aryl vinylsulfonate ester compounds (1-27):  
 Synthesis of all aryl vinylsulfonates were carried out using a literature reported protocol 
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. 
4-Bromophenyl ethenesulfonate (1): Pale yellow semi solid. Rf = 0.46. Hexane: EtOAc (8:2). 
Yield: 61%.
1
H NMR (400 MHz CDCl3) δ ppm: 6.19 (d, J = 10.0Hz, 1H), 6.36 (d, J = 15.1Hz, 





NMR (100 MHz CDCl3) δ ppm: 120.9, 123.7 131.7, 132.3, 133.0, 148.3. HRMS [ESI-MS +ve] 
calculated for (C8H7BrO3S+H)
+
: 262.9378, observed: 262.9375. 
Quinoline-8-yl ethenesulfonate (2): Colorless solid Rf = 0.21.Hexane: EtOAc (8:2). Yield: 65%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.05 (d, J= 10.2Hz, 1H), 6.35 (d, J= 15.1Hz, 1H), 7.11 (dd, 
J= 15.1Hz and 10.2Hz, 1H), 7.50 (dd, J= 5.2Hz and 5.3Hz, 1H), 7.56 (m, 1H), 7.72 (d, J= 5.3Hz, 
1H), 7.81 (d, J= 5.3Hz, 1H), 8.25 (d, J= 5.3Hz, 1H), 8.98 (s, 1H). 
13
C NMR (100MHz, CDCl3) δ 
ppm: 122.1, 123.3, 126.2, 127.2, 129.7, 130.2, 133.4, 136.1, 141.3, 145.3, 150.9. HRMS [ESI-
MS +ve] calculated for (C11H9NO3S+H)
+
: 236.0376, observed: 236.0375. 
5-Nitroquinoline-8-yl ethenesulfonate (3): Colorless solid. Rf = 0.24. Hexane: EtOAc (8:2). 
Yield: 68%. 
1
H NMR (400MHz, CDCl3)  δ ppm: 6.15 (d, J= 8.2Hz, 1H), 6.45 (d, J= 16.1Hz, 
1H), 7.11, (dd, J= 16.1Hz and 8.2Hz, 1H), 7.74 (dd, J= 4.1Hz and 8.2Hz, 1H), 7.83 (d, J= 8.5Hz, 
1H), 8.44 (d, J= 8.5Hz, 1H), 9.07 (d, J= 8.3Hz, 1H), 9.11 (d, J= 4.1Hz, 1H). 
13
C NMR (100MHz, 
CDCl3) δ ppm: 121.5, 122.9, 124.8, 124.9, 131.3, 132.4, 133.2, 141.2, 143.7, 149.7, 151.9. 
HRMS [ESI-MS +ve] calculated for (C11H8N2O5S+H)
+
: 281.0227, observed: 281.0227 . 
[1, 1’-Biphenyl]-4-yl ethenesulfonate (4): white powder. Rf = 0.28. Hexane: EtOAc (9:1). Yield: 
76%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.19 (d, J= 10.1Hz, 1H), 6.41 (d, J= 16.6Hz, 1H), 6.70 
(dd, J= 10.1Hz and 16.6Hz, 1H), 7.30 (m, 2H), 7.33-7.47 (m, 3H), 7.57 (m, 4H). 
13
C NMR 
(100MHz, CDCl3) δ ppm: 122.6, 127.1, 127.8, 128.5, 128.9, 131.8, 132.1, 139.8, 140.6, 148.7. 
HRMS [ESI-MS +ve] calculated for (C14H12O3S+Na)
+
: 283.0399, observed: 283.0399. 
4’-Nitro-[1, 1’-biphenyl]-4-yl ethenesulfonate (5): yellow powder. Rf = 0.25. Hexane: EtOAc 
(8:2). Yield: 72%. 
1
H NMR (400MHz, DMSO-D6) δ ppm: 6.35 (d, J= 16.8Hz, 1H), 6.43 (d, J= 
10.1 Hz, 1H), 7.30 (dd, J= 10.1Hz and 16.8Hz, 1H), 7.46 (d, J= 8.7Hz, 2H), 7.90 (d, J= 8.5Hz, 
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2H), 7.98 (d, J= 8.7Hz, 2H), 8.32 (d, J= 8.7Hz, 2H). 
13
C NMR (100MHz, DMSO-D6) δ ppm: 
123.1, 124.1, 128.0, 129.1, 132.2, 133.6, 136.9, 145.1, 146.9, 149.5. HRMS [ESI-MS +ve] 
calculated for (C14H11NO5S+H): 328.0250, observed: 328.0247. 
Methyl 2-((vinylsulfonyl) oxy) benzoate (6): Viscous liquid Rf = 0.51. Hexane: EtOAc (8:2). 
Yield: 67%. 
1
H NMR (500MHz, CDCl3) δ ppm: 3.93 (s, 3H), 6.16 (d, J= 10.1Hz, 1H), 6.37 (d, 
J= 14.9Hz, 1H), 6.82 (dd, J= 14.91Hz and 10.1Hz, 1H), 7.39 (m, 2H), 7.57 (t, J= 10.4Hz, 1H), 
7.97 (d, J= 10.4Hz, 1H). 
13
C NMR (100MHz, CDCl3) δ ppm: 52.5, 124.1, 124.8, 127.2, 131.3, 
132.1, 132.7, 133.7, 147.8, 164.9. HRMS [ESI-MS +ve] calculated for (C10H10O5S+Na)
+
: 
265.0141, observed: 265.0141. 
Methyl 4-((vinylsulfonyl) oxy) benzoate (7): white powder. Rf = 0.59. Hexane: EtOAc (8:2). 
Yield: 62%. 
1
H NMR (400MHz, CDCl3) δ ppm: 3.92 (s, 3H), 6.23 (d, J= 10.2Hz, 1H), 6.39 (d, 
J= 14.9Hz, 1H), 6.73 (dd, J= 14.9Hz and 10.2Hz, 1H), 7.31 (d, J= 10.1 Hz, 2H), 8.08 (d, J= 
10.1Hz, 2H). 
13
C NMR (100MHz, CDCl3) δ ppm: 52.4, 122.2, 129.2, 131.5, 131.9, 132.3, 152.6, 
165.9. HRMS [ESI-MS +ve] calculated for (C10H10O5S+H)
+
: 243.0322, observed: 243.0322. 
4-Cyanophenyl ethenesulfonate (8): Yellow powder. Rf = 0.20. Hexane: EtOAc (9:1). Yield: 
73%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J= 9.9Hz, 1H), 6.43 (d, J= 16.6Hz, 1H), 6.70 
(dd, J= 16.6Hz and 9.9Hz, 1H), 7.37 (d, J= 8.7Hz, 2H), 7.72 (d, J= 8.6Hz, 2H). 
13
C NMR 
(100MHz, CDCl3) δ ppm: 111.4, 117.6, 123.3, 131.8, 132.7, 134.1, 152.2. HRMS [ESI-MS +ve] 
calculated for (C9H7NO3S+H): 210.0219, observed: 210.0221.  
4-Nitrophenyl ethenesulfonate (9): white powder. Rf = 0.49. Hexane: EtOAc (8:2). Yield: 69%. 
1
H NMR (500MHz, CDCl3) δ ppm: 6.30 (d, J= 9.7Hz, 1H), 6.46 (d, J= 14.8Hz, 1H), 6.74 (dd, J= 
14.8Hz and 9.7Hz, 1H), 7.44 (d, J= 9.8Hz, 2H), 8.30 (d, J= 9.8Hz, 2H). 
13
C NMR (125MHz, 
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CDCl3) δ ppm: 123.1, 125.6, 131.5, 133.2, 146.3, 153.5. HRMS [ESI-MS +ve] calculated for 
(C8H7NO5S+H)
+
: 230.0118, observed: 230.0118. 
5-Fluoro-2-nitrophenyl ethenesulfonate (10): yellow viscous liquid. Rf = 0.29. Hexane: EtOAc 
(9:1). Yield: 56%.
1
H NMR (400Hz, CDCl3) δ ppm: 6.27 (d, J= 9.6 Hz, 1H), 6.52 (d, J= 15.8 Hz, 
1H), 6.76 (dd, J= 15.8 Hz and 9.6 Hz, 1Hz), 7.23 (m,1H), 7.31 (m, 1H), 8.17 (m, 1H). 
13
C NMR 
(100MHz, CDCl3) δ ppm: 113.5 (d, JC-F= 26.1 Hz), 115.0 (d, JC-F= 23.2 Hz), 128.1 (d, JC-F= 10.1 
Hz), 132.1, 133.2, 139.0, 143.8, 165.3 (d, JC-F= 258.2 Hz).HRMS [ESI-MS +ve] calculated for 
(C8H6FNO5S+Na)
+
: 269.9843, observed: 269.9841. 
4-Chlorophenyl ethenesulfonate (11): pale yellow viscous liquid. Rf = 0.27 Hexane: EtOAc (9:1). 
Yield: 68%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.21 (d, J= 9.9Hz, 1H), 6.39 (d, J= 16.7Hz, 1H), 
6.67 (dd, J= 16.7Hz and 9.9Hz, 1H), 7.19 (d, J= 9.0, 2H), 7.36 (d, J= 9.0, 2H). 
13
C NMR 
(100MHz, CDCl3) δ ppm: 123.7, 129.9, 131.7, 132.3, 133.1, 147.7. HRMS [ESI-MS +ve] 
calculated for (C8H7ClO3S+H)
+
: 218.9877, observed: 218.9877. 
2-Chlorophenyl ethenesulfonate (12): pale yellow viscous liquid. Rf = 0.25. Hexane: EtOAc 
(9.5:0.5). Yield: 68%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.18 (d, J= 10.4Hz, 1H), 6.37 (d, J= 
16.6Hz, 1H), 6.78 (dd, J= 16.6Hz and 10.4Hz, 1H), 7.25 (t, J= 7.7Hz, 1H), 7.30 (t, J= 7.7Hz, 
1H), 7.42 (d, J= 8.1Hz, 1H), 7.44 (d, J= 8.1Hz, 1H). 
13
C NMR (100MHz, CDCl3) δ ppm:  124.5, 
127.1, 128.1, 128.2, 130.9, 131.8, 132.4, 145.3. HRMS [ESI-MS +ve] calculated for 
(C8H7ClO3S+Na)
+
: 240.9697, observed: 240.9699. 
3-Chlorophenyl ethenesulfonate (13): colorless viscous liquid. Rf = 0.25 Hexane: EtOAc 
(9.5:0.5). Yield: 70%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.21 (d, J= 9.9Hz, 1H), 6.40 (d, J= 





NMR (100MHz, CDCl3) δ ppm:  120.6, 122.8, 127.7, 130.6, 131.8, 132.3, 135.1, 149.6. HRMS 
[ESI-MS +ve] calculated for (C8H7ClO3S+H)
+
: 218.9877, observed: 218.9877. 
4-Chloro-2-fluorophenyl ethenesulfonate (14): colorless viscous liquid. Rf = 0.48    Hexane: 
EtOAc (8:2). Yield: 63%.
1
H NMR (400MHz, CDCl3) δ ppm: 6.22 (d, J= 10.0Hz, 1H), 6.39 (d, 
J= 16.6Hz, 1H), 6.72 (d, J= 16.6Hz and 10.0Hz, 1H), 7.21 (m, 2H), 7.34 (m, 1H). 
13
C NMR 
(100MHz, CDCl3) δ ppm:  117.9 (d, JC-F= 21.1 Hz, 1C), 125.2 (d, JC-F= 3.6 Hz, 1C), 125.8, 
131.7, 132.4, 133.5 (d, JC-F= 8.8 Hz, 1C), 135.4 (d, JC-F= 12.6 Hz, 1C), 154.1 (d, JC-F= 250.1 Hz, 
1C).HRMS [ESI-MS +ve] calculated for (C8H6ClFO3S+Na)
+
: 258.9602, observed: 258.9604. 
4-Chloro-3-fluorophenyl ethenesulfonate (15): colorless viscous liquid. Rf = Hexane: EtOAc 
(9:1). Yield: 64%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J=9.9 Hz, 1H), 6.41 (d, J=16.6 
Hz, 1H), 6.68 (dd, J= 16.6 Hz and 9.9 Hz, 1H), 7.01 (m, 1H), 7.12 (m, 1H), 7.43 (m, 1H). 
13
C 
NMR (100MHz, CDCl3) δ ppm:  111.6 (d, JC-F= 24.2 Hz) 119.0 (d, JC-F= 4.1 Hz) 120.3 (d, JC-F= 
17.7 Hz) 131.1, 131.6, 132.8, 148.2 (d, JC-F= 9.3 Hz,), 158.0 (d, JC-F= 251.8 Hz) HRMS [ESI-MS 
+ve] calculated for (C8H6ClFO3S+H)
+
: 236.9783, observed: 236.9783. 
4-Chloro-3-(trifluoromethyl) phenyl ethenesulfonate (16): colorless viscous liquid. Rf = 0.32. 
Hexane: EtOAc (9:1). Yield: 57%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.27 (d, J= 9.8Hz, 1H), 
6.42 (d, J= 16.6Hz, 1H), 6.71 (d, J= 16.6Hz and 9.8Hz, 1H), 7.40 (m, 1H), 7.55 (m, 2H).  
13
C 
NMR (100MHz, CDCl3) δ ppm: 121.7 (q, JC-F= 121.9 Hz), 122.2 (q, JC-F= 270.1 Hz), 126.9, 
131.1, 132.5, 133.0, 133.1, 147.3 HRMS [ESI-MS +ve] calculated for (C9H6ClF3O3S+Na)
+
: 
308.9570, observed: 308.9572. 
4-Chloro-2, 3, 5, 6-tetrafluorophenyl ethenesulfonate (17): colorless liquid. Rf = 0.24 Hexane: 
EtOAc (9.8:0.2). Yield: 66%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.35 (d, J= 9.9Hz, 1H), 6.56 
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(d, J= 16.5Hz, 1H), 6.81 (dd, J= 16.5Hz and 9.9Hz, 1H). 
13
C NMR (100MHz, CDCl3) δ ppm: 
131.8, 133.1, 140.3, 143.1, 143.2, 145.6 HRMS [ESI-MS +ve] calculated for 
(C8H3ClF4O3S+Na)
+
: 312.9320, observed: 312.9323. 
4-Chloro-3-methylphenyl ethenesulfonate (18): colorless viscous liquid. Rf = 0.32.  Hexane: 
EtOAc (9:1). Yield: 80%. 
1
H NMR (400MHz, CDCl3) δ ppm: 2.35 (s, 3H), 6.19 (d, J= 10.3Hz, 
1H), 6.35 (d, J= 16.7Hz, 1H), 6.68 (dd, J= 10.3Hz and 16.7 Hz, 1H), 7.00 (dd, J= 2.9Hz and 8.8 
Hz, 1H), 7.10 (d, J= 2.8Hz, 1H), 7.30 (d, J= 8.6Hz, 1H). 
13
C NMR (100MHz, CDCl3) δ ppm: 
20.2, 120.9, 124.6, 130.1, 131.8, 132.3, 133.1, 138.1, 147.6. HRMS [ESI-MS +ve] calculated for 
(C9H9ClO3S+Na)
+
: 254.9853, observed: 254.9855. 
4-Chloro-3, 5-dimethylphenyl ethenesulfonate (19): white powder. Rf = 0.43. Hexane: EtOAc 
(8:2). Yield: 59%. 
1
H NMR (500MHz, CDCl3) δ ppm: 2.27 (s, 6H), 6.10 (d, J= 5.5Hz, 1H), 6.28 
(d, J= 20.0Hz, 1H), 6.59 (dd, J= 20.0Hz and 5.5Hz, 1H), 6.87 (s, 2H). 
13
C NMR (100MHz, 
CDCl3) δ ppm: 20.8, 121.8, 131.9, 132.1, 133.3, 138.6, 146.9 HRMS [ESI-MS +ve] calculated 
for (C10H11ClO3S+Na)
+
: 269.0010, observed: 269.0010. 
4-Chloro-2-nitrophenyl ethenesulfonate (20): pale yellow viscous liquid. Rf = 0.24 Hexane: 
EtOAc (9:1). Yield: 72%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.29 (d, J= 9.9Hz, 1H), 6.49 (d, J= 
16.7Hz, 1H), 6.81 (dd, J= 16.7Hz and 9.9Hz, 1H), 7.52 (d, J= 8.9, 1H), 7.65 (dd, J= 8.9Hz and 
2.5Hz, 1H), 8.01 (d, J= 2.5Hz, 1H). 
13
C NMR (100MHz, CDCl3) δ ppm: 126.1, 126.7, 131.9, 
133.1, 133.4, 134.5, 139.8, 142.5. HRMS [ESI-MS +ve] calculated for (C8H6ClNO5S+Na)
+
: 
285.9547, observed: 285.9547. 
3, 4-Dichlorophenyl ethenesulfonate (21): colorless viscous liquid. Rf = 0.33. Hexane: EtOAc 
(9:1). Yield: 67%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.25 (d, J= 9.9Hz, 1H), 6.41 (d, J= 
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16.6Hz, 1H), 6.68 (dd, J= 16.6Hz and 9.9Hz, 1H), 7.12 (dd, J= 8.8Hz and 2.7Hz, 1H), 7.39 (d, 
J= 2.7Hz, 1H), 7.47 (d, J= 8.8Hz, 1H).
 13
C NMR (100MHz, CDCl3) δ ppm: 121.9, 124.5, 131.2, 
131.5, 131.7, 132.8, 133.4, 147.6. HRMS [ESI-MS +ve] calculated for (C8H6Cl2O3S+H)
+
: 
252.9487, observed: 252.9489. 
2, 4, 5-Trichlorophenyl ethenesulfonate (22): white powder. Rf = 0.48 Hexane: EtOAc (8:2). 
Yield: 59%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.26 (d, J= 8.5Hz, 1H), 6.45 (d, J= 16.1Hz, 1H), 
6.77 (dd, J= 16.1Hz and 8.5Hz, 1H), 7.56 (s, 1H), 7.57 (s, 1H). 
13
C NMR (100MHz, CDCl3) δ 
ppm: 125.9, 126.3,131.4, 131.9, 132.1,132.7, 143.8. HRMS [ESI-MS +ve] calculated for 
(C8H5Cl3O3S+H)
+
: 286.9098, observed: 286.9101. 
2, 4, 6-Trichlorophenyl ethenesulfonate (23): white powder. Rf = 0.44 Hexane: EtOAc (9:1). 
Yield: 63%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.26 (d, J= 10.3Hz, 1H), 6.56 (d, J= 16.5Hz, 
1H), 6.94 (d, J= 16.5 Hz and 10.3Hz, 1H), 7.4 (s, 2H),
 13
C NMR (100MHz, CDCl3) δ ppm: 
126.7, 128.3, 128.8, 130.6, 131.4, 139.5. HRMS [ESI-MS +ve] calculated for 
(C8H5Cl3O3S+Na)
+
: 308.8917, observed: 308.8919. 
Methyl 5-chloro-2-((vinylsulfonyl) oxy) benzoate (24): pale yellow viscous liquid. Rf = 0.23. 
Hexane: EtOAc (9.5:0.5). Yield: 60%. 
1
H NMR (400MHz, CDCl3) δ ppm: 3.95 (s, 3H), 6.18 (d, 
J= 10.0Hz, 1H), 6.37 (d, J= 16.7Hz, 1H), 6.81 (dd, J= 16.7Hz and 10.0Hz, 1H), 7.34 (d, J= 
8.7Hz, 1H), 7.50 (d, J= 8.7Hz, 1H), 7.93 (s, 1H).
 13
C NMR (100MHz, CDCl3) δ ppm: 52.7, 
125.5, 126.1, 131.8, 132.4, 132.9, 133.5, 133.88, 146.2, 163.6. HRMS [ESI-MS +ve] calculated 
for (C10H9ClO5S+Na)
+
: 298.9751, observed: 298.9751. 
4-Fluorophenyl ethenesulfonate (25): colorless viscous liquid. Rf = 0.25. Hexane: EtOAc (9:1). 
Yield: 69%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.10 (d, J= 10.0Hz, 1H), 6.37 (d, J= 16.7Hz, 
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1H), 6.66 (dd, J= 10.0Hz and 16.7Hz, 1H), 7.10 (m, 2H), 7.22 (m, 2H). 
13
C NMR (100 MHz, 
CDCl3) δ ppm: 116.6 (d, JC-F= 29.0Hz,), 124.0 (d, JC-F= 9.2 Hz,), 131.8, 132.1, 145.1 (d, JC-F= 
3.5Hz,), 161.7 (d, JC-F= 247.3Hz, 1C). HRMS [ESI-MS +ve] calculated for (C8H7FO3S+H)
+
: 
203.0173, observed: 203.0174. 
4-Iodophenyl ethenesulfonate (26): colorless viscous liquid. Rf = 0.29. Hexane: EtOAc (9:1). 
Yield: 64%. 
1
H NMR (400MHz, CDCl3) δ ppm: 6.19 (d, J= 10.0Hz, 1H), 6.37 (d, J= 16.8Hz, 
1H), 6.65 (dd, J= 16.8Hz and 10.0Hz, 1H), 6.99 (d, J= 8.7Hz, 2H), 7.70 (d, J= 8.7Hz, 2H). 
13
C 
NMR (100MHz, CDCl3) δ ppm: 91.9, 124.4, 131.7, 132.3, 139.1, 149.2. HRMS [ESI-MS +ve] 
calculated for (C8H7IO3S+Na)
+
: 332.9053, observed: 332.9056. 
2-Ethylphenyl ethenesulfonate (27): pale yellow viscous liquid. Rf = 0.37. Hexane: EtOAc (9:1). 
Yield: 64%. 
1
H NMR (400MHz, CDCl3) δ ppm: 1.22 (t, J= 7.6Hz, 3H), 2.71 (q, J= 7.6Hz, 2H), 
6.14 (d, J= 9.9Hz, 1H), 6.38 (d, J= 16.6Hz, 1H), 6.72 (dd, J= 16.6Hz and 9.9Hz, 1H), 7.23 (m, 
4H).
13
C NMR (100MHz, CDCl3) δ ppm: 14.2, 23.1, 121.9, 127.1, 127.4, 130.1, 131.2, 132.7, 
137.0, 147.6. HRMS [ESI-MS +ve] calculated for (C10H12O3S+Na)
+
: 235.0399, observed: 
235.0401. 
The synthetic scheme utilized in the development of cathepsin L inhibitor KD-1 
Inhibitor KD-1 was synthesized by following scheme 3.1  
(i). Synthesis of ethyl (diethoxyphosphoryl)methanesulfonate (I). This compound was 
synthesized by following the literature reported protocol
144
 and its characterization was found to 





(ii) Synthesis of tert-butyl (4-methyl-1-oxopentan-2-yl)carbamate (II). This compound was 
synthesized by following the literature reported protocol and its characterization was found to be 
consistent with the previously reported NMR spectra 
143
. 
(iii).Synthesis of ethyl (E)-3-((tert-butoxycarbonyl)amino)-5-methylhex-1-ene-1- sulfonate (III). 
This compound was prepared using a literature reported protocol with appropriate 
modification
130
 . A solution of ethyl (diethoxyphosphoryl)methanesulfonate (483 mg, 1.86 
mmol, 1 equiv) in anhydrous tetrahydrofuran (4 mL) was added dropwise to a stirring suspension 
of sodium hydride (58 mg, 2.41 mmol) in anhydrous tetrahydrofuran (3 mL) at 0°C under inert 
condition. After 30 min, a solution of N-BOC-L-leucinal in anhydrous tetrahydrofuran (5 mL) 
was added to the reaction mixture. Stirring was continued for an hour. The reaction was 
quenched by an addition of 5 mL of saturated ammonium chloride solution. The solution was 
concentrated under vacuum, diluted with water (10 mL), and extracted with ethylacetate (3×25 
mL). The combined organic extracts were washed brine and dried over sodium sulfate, filtered, 
and concentrated under vacuum. Purification by flash column chromatography (silica gel; 90:10 
hexane/ethylacetate) provided 419 mg (yield: 70%) of product. Rf = 0.6 (80:20 
hexane/ethylacetate). 
1
H NMR (500 MHz, CDCl3) δ ppm: 0.94 (m, 6H), 1.37 (t, J= 6.9 Hz, 3H), 
1.44 (s,11H), 1.70 (m,1H), 4.16 (q, J= 6.9 Hz, 2H), 4.37 (m,1H), 4.73 (m,1H), 6.31 (d, 15.2 Hz, 
1H), 6.79 (dd, J= 15.2 and 5.4 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ ppm: 15.1, 22.0, 23.1, 
24.8, 28.3, 43.4, 49.7, 67.3, 80.1, 124.4, 149.5, 155.3. HRMS [ESI-MS +ve] calculated for 
(C14H27NO5S + Na)
+
: 344.1508, observed 344.1528. 




  To a stirred solution of the BOC-protected amine III (180 mg, 0.56 mmol) was added 
25% solution of trifluoroacetic acid in dichloromethane (5 ml) and stirred for 1 hr. The solution 
was removed in vacuo. The residue was dissolved in DMF(2 ml). To this was added a cocktail of 
N-Cbz-L-phenylalanine (168 mg, 0.56 mmol), HCTU (232mg, 0.56 mmol) and N,N-
diisopropylethylamine (375μl, 2.15 mmol) as a solution in anhydrous DMF (5 ml) at 0°C. Once 
the addition was done, ice bath was removed and the reaction was stirred overnight. The reaction 
was then diluted with 50 ml of ethyl acetate and washed with saturated ammonium chloride 
solution (25 ml), saturated sodium bicarbonate solution, and with brine (25 ml). The organic 
layer was dried over sodium sulfate and concentrated in vacuo.  Purification by flash column 
chromatography (silica gel; 80:20 hexane/ethylacetate) provided 169 mg (yield: 60%) of product. 
Rf =0.21(80:20 hexane/ethylacetate). 
1
H NMR (400 MHz, CDCl3) δ ppm: 0.86 (m, 6H), 1.31 (m, 
2H), 1.37 (t, J= 6.9 Hz, 3H), 1.51 (m,1H), 3.05 (dd, J= 14.4 and 7.7 Hz, 1H), 3.11 (dd, J= 14.4 
and 6.4 Hz, 1H), 4.13 (m, 2H), 4.38 (m, 1H), 4.62 (m, 1H), 5.08 (m, 2H), 5.35 (bs, 1H), 5.94 (d, 
15.4 Hz, 2H), 6.61 (dd, J= 15.4 and 5.2 Hz, 1H), 7.17 (m, 2H), 7.32 (m,8H). 
13
C NMR (100 
MHz, CDCl3) δ ppm: 14.9, 21.9, 22.7, 24.6, 38.2, 42.7, 48.0, 56.5, 67.0, 67.3, 124.5, 127.6, 
128.2, 128.4, 128.6, 129.2, 129.2, 135.8, 135.9, 147.7, 156.1, 170.6. HRMS [ESI-MS +ve] 
calculated for (C26H34N2O6S + H)
+
: 503.2217, observed 503.2218. 
(v). Synthesis of 4-bromophenyl (E)-3-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-
5-methylhex-1-ene-1-sulfonate (KD-1) 
 This compound was prepared using a literature reported protocol with appropriate 
modification 
150
. To a stirred solution of IV (150 mg, 0.3 mmol) in acetone was added tetrabutyl 
ammonium iodide (45 mg, 0.3 mmol) and refluxed for overnight. The mixture was concentrated 
in vacuo and was dissolved in anhydrous dichloromethane (2 ml). This was added to a stirred 
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solution of triphenyl phosphine (157 mg, 0.6 mmol) and sulfuryl chloride (53 μl, 0.664 mmol) in 
anhydrous dichloromethane (4 ml) at 0°C. Once the addition was done, ice bath was removed 
and the reaction was stirred overnight. The mixture was then concentrated in vacuo and passed 
through silica (oven dried) using hexane and ethyl acetate (90:10) to recover sulfonyl chloride as 
white solid. Subsequently, the sulfonyl chloride (100mg, 0.23 mmol) was dissolved in anhydrous 
dichloromethane (3 ml). 4-bromophenol (60 mg, 0.345 mmol) was added to the solution 
followed by addition of triethylamine (100 μl, 0.69 mmol) at 0°C. The mixture was stirred for 
one hr and diluted with ethyl acetate (30 ml) followed by washing with saturated ammonium 
chloride solution (15 ml), saturated sodium bicarbonate solution (15ml ×3), and with brine (15 
ml). The organic layer was dried over sodium sulfate and concentrated in vacuo.  Purification by 
flash column chromatography (silica gel; 90:10 hexane/ethylacetate) provided 40 mg (overall 
yield: 22%) of the product as white solid. Rf =0.37 (80:20 hexane/ethylacetate). 
1
H NMR (400 
MHz, CDCl3) δ ppm: 0.82 (m, 6H), 1.22 (m, 2H), 1.41 (m, 1H), 3.0 (dd, J= 13.7 and 7.9 Hz, 
1H), 3.11 (dd, J= 13.7 and 6.4 Hz, 1H), 4.38 (m,1H), 4.52 (m, 1H), 5.07(m, 2H), 5.4 (bs,1H), 
5.93(bs, 1H), 6.03(d, J=15.1 Hz, 1H), 6.46(dd, J= 15.1 and 5.2 Hz, 1H), 7.08 (m, 2H), 7.13 (m, 
2H), 7.33 (m, 8H), 7.51 (m, 2H). 
13
C NMR (100 MHz, CDCl3) δ ppm: 21.8, 22.5, 24.5, 38.3, 
42.2, 48.2, 56.6, 67.4 120.8, 123.7, 124.5, 127.6, 128.2, 128.4, 128.6, 129.1, 129.1, 132.9, 135.8, 
135.8, 148.3, 150.1, 156.1, 170.6. HRMS [ESI-MS +ve] calculated for (C30H33BrN2O6S +H)
+
: 
629.1322, observed 629.1315. 
3.6.2. Screening and Enzymology 
General. Following enzymes and their substrates were purchased from Enzo Life Sciences 
(Farmingdale, NY, USA): cathepsin L (BML-SE201), cathepsin K (BML-SE553), cathepsin B 
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(BML-SE198), cathepsin D (BML-SE199), cathepsin S (BML-SE453), cathepsin H (BML-
SE200), cathepsin G (BML-SE283), human PTP1B (BML-SE332), Z-Arg-Arg-pNA (BML-
P138), Z-Gly-Pro-Arg-AMC (BML-P142), Z-Phe-Arg-AMC (BML-P139), H-Arg-AMC.2HCl 
(BML-P135), Suc-Ala-Ala-Pro-Phe-pNA (BML-P141), Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-
Leu-Lys(Dnp)-D-Arg-NH2 (BML-P145), Z-Val-Val-Arg-AMC (BML-P199). N-alpha-Benzoyl-
DL-arginine-p-nitroanilide (BAPNA) (B4875), trypsin (T1426), para-nitrophenylphosphate were 
purchased from Sigma–Aldrich (St. Louis, MO, USA). All the biological grade buffers were 
used and were purchased from Sigma–Aldrich (St. Louis, MO, USA). All enzyme kinetics 
experiments (unless otherwise stated) were carried out at 30°C in appropriate buffer condition 
with 5% DMSO concentration. For measuring the initial rates of enzyme catalyzed reaction, a 
temperature-controlled steady-state arc lamp fluorometer equipped with Felix 32 software 
(Photon Technology Instrument, Birmingham, NJ, USA) and a UV–Vis spectro-photometer 
(Modelk25; Perkin Elmer Inc., Waltham, MA, USA) was used. 
Screening of aryl vinylsulfonate library compounds:  
 The inactivation reaction of human liver cathepsin L (net 50 nM) by 10 μM of inhibitor 
was performed under pseudo first order condition ([I]>>[E]) in a 0.5 ml eppendorf tube 
maintained at 30°C in a temperature controlled bath. A previously reported cathepsin L assay 
procedure was employed 
151
. Cathepsin L enzyme was first activated for 10 min in sodium 
acetate buffer (400 mM, pH 5.5) containing 8 mM DTT and 4 mM Na2EDTA. The inactivation 
reaction was initiated by the addition of inhibitor where DMSO concentration was maintained at 
5%. After suitable time intervals, an aliquot of 8μl of incubation mixture was withdrawn and 
added to an assay mixture (net assay volume 200μl) that contained 5 μM of Z-FR-AMC (Km= 




4 (87±5) 2 ( 9±1) 3 (57±3) 5 (70±4) 6 (34±4) 7 (87±2) 8 (88±3) 
9 (90±2) 10 (5±2) 11 (31±5) 13 (32±3) 12 (17±2) 14 (74±4) 15 (64±4) 16 (69±5) 
17 (80±7) 18 (82±2) 19 (46±5) 20 (29±1) 21 (56±4) 22 (26±3) 23 (29±7) 24 (4±2) 
25 (32±3) 26 (85±3) 
1 (95±3) 
Figure 3.5. Chemical structures of the synthesized aryl vinylsulfonate library (1-27)  
targeted for cathepsin L inhibition. Time-dependent inhibition experiments were 
performed under pseudo-first order condition at 10 µM inhibitor concentration, as  
described in the main text. In parenthesis, % inhibition is calculated from two  
independent experiments.     
nm) and the enzyme activity was determined by measuring the initial rates of substrate turnover 






Determination of IC50 of KD-1 against cathepsin L: 
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Figure 3.6. Dose response curve   for KD-1 mediated  
inhibition of human liver cathepsin L. The points are 
 experimental and the line joining them is the fit to  
obtain the IC50 value as 3.6±0.1 nM. 
 Briefly IC50 , experiment 
was performed by subsequent 
addition of active cathespsin L 
(160 pM) and 5 μM of Z-FR-
AMC in acetate buffer (pH 5.5) 
containing KD-1 (concentration 
ranging from 0 pM to 15 nM) at 
30°C. Net DMSO concentration 
was maintained at 8%. The 
reaction was monitored 
fluorometrically (excitation: 365 
nm; emission: 440 nm) for 100 
seconds at 30°C. The experimental data thus obtained were plotted using SigmaPlot software and 
fitted using Enzyme Kinetics module to obtain IC50 value. The IC50 value thus obtained was 
3.6±0.1 nM (Figure 3.6).  
Determination of kinetic inactivation parameters of KD-1 against cathepsin L: 
 The inactivation reaction of human liver cathepsin L (net 160 pM) by appropriate 
concentrations of KD-1 was performed under pseudo first order condition ([I]>>[E]) in a 
fluorescence quartz cuvette maintained at 30°C. Briefly, the inactivation reaction was performed 
by subsequent addition of active cathespsin L (160 pM) and 5 μM of Z-FR-AMC in acetate 
buffer (pH 5.5) containing KD-1 (concentration ranging from 1 nM to 20 nM). Net DMSO 
concentration was maintained at 8%. The reaction was monitored fluorometrically (excitation: 
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Figure 3.7. Determination of second order inactivation  
rate constant (k
inact
) for KD-1-mediated inhibition of  
human liver cathepsin L. The k
obs 
obtained from the  
progress curve fit were plotted against appropriate  
concentration of [KD-1]. The slope of the line yielded 
the enzyme inactivation rate constant k
inact
. 
365 nm; emission: 440 nm) for 3 minutes at 30°C. Subsequently, the progress curves were 
analyzed using non-linear regression according the following equation.
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P = vz [1- exp (-kobs* t)] / kobs; 
where [P] is the product, vz is the initial velocity (at time zero), and kobs is the pseudo-first order 
rate constant.  
 Pseudo-first order rate constants kobs were plotted against appropriate inhibitor 
concentrations [I], and 2nd order inactivation rate constant kinact  was calculated from the slope of 
the plot according to following 
equation 
58
 (Figure 3.7); 
kobs = kinact [I] / [1+ ([S]/KM)] 
where kobs is the pseudo-first order 
rate constant, [I] is the inhibitor 
concentration, [S] is the substrate 
concentration, with a given KM . 
The data were analyzed using 







Selectivity profile of KD-1 against other enzymes 
Determination of kinetic inactivation parameters of KD-1 against cathepsin S 
 A previously reported cathepsin S assay procedure was followed with suitable 
modification 
152
. Thus, recombinant human cathepsin S enzyme was activated in the 100 mM 
potassium phosphate buffer (pH 6.5) containing 2.5 mM DTT, 2.5 mM Na2EDTA for 10 min. 
The inactivation reaction of cathepsin S (net 1 nM) by appropriate concentrations of KD-1 was 
performed under pseudo first order condition ([I]>>[E]) in a fluorescence quartz cuvette 
maintained at 30°C. Briefly, the inactivation reaction was initiated by subsequent addition of 
active cathepsin L and 50 μM of Z-VVR-AMC (KM = 17.7 μM) in phosphate buffer (pH 6.5) 
containing KD-1 (concentration ranging from 20 nM to 200 nM). Net DMSO concentration was 
maintained at 8%.. The reaction was monitored fluorometrically (excitation: 365 nm; emission: 
440 nm) for 3 minutes at 30°C. The progress curves were analyzed using the same equations 
used for cathepsin L assay. 
Cathepsin K inhibition assay 
 For assaying cathepsin K activity, a previously published protocol was followed with 
appropriate modification 
153
. Thus, recombinant human cathepsin K enzyme was activated in the 
50 mM sodium acetate buffer (pH 5.5) containing 2.5 mM DTT, 2.5 mM Na2EDTA for 10 min. 
The inactivation reaction of cathepsin K (net 50 nM) with inhibitor KD-1(250 nM) was initiated 
under pseudo first order condition ([I]>>[E]). After suitable time intervals, an aliquot of 10 μl of 
incubation mixture was withdrawn and the enzyme activity was monitored fluorometrically in 
assay buffer (200 μl; 7.5% DMSO) containing 200 μM of Z-GPR-AMC (KM =68 μM; Ex/Em: 
365/440 nm). The data thus obtained was plotted and fitted to the following equation: 
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At = Af – (Af – A0) exp (-kobs*t) 
 where At = enzyme activity at time t of cathepsin K inactivation, Af = final cathepsin K 
activity at infinite time of inactivation, A0 = initial enzyme activity at zero time of inactivation, 
and kobs = pseudo-first order rate constant of inactivation. The data were analyzed using 
KaleidaGraph (version 3.52). 
Cathepsin H inhibition assay 
 For assaying cathepsin H activity, a previously published protocol was followed with 
appropriate modification 
151a
. Thus, human liver cathepsin H enzyme was activated in the 200 
mM KH2PO4 / 200 mM Na2HPO4 buffer (pH 6.8) containing 5 mM DTT, 2 mM Na2EDTA for 
10 min. The inactivation reaction of cathepsin H (net 330 nM) with inhibitor KD-1 (100 μM) 
was initiated under pseudo first order condition ([I]>>[E]). After suitable time intervals, an 
aliquot of 10 μl of incubation mixture was withdrawn and the enzyme activity was monitored 
fluorometrically in assay buffer (200 μl; 8% DMSO) containing 300 μM of H-R-AMC.2HCl (KM 
= 150 μM; Ex/Em: 365/440 nm). 
*Assays involving cathepsin B, cathepsin D, cathepsin G, trypsin and PTP1B were carried out 
according to the literature reported protocol 
94
. 
3.6.3. Biological and Cell-Based Studies 
Inhibition of Cathepsin L’s Collagenase Activity by KD-1 
 This experiment was carried out by following slight modification of a literature reported 
protocol 
154
.  Human skin type I collagen (Calbiochem) was dissolved in 100 mM acetic acid for 
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24 h at room temperature to give a final concentration of 1.0 mg/ml. In 500 µl eppendorf tubes, 
different concentrations of KD-1 (0 nM, 300 nM, 500 nM and 1000 nM) were incubated with 
200 nM of active cathepsin L (Assay Condition: 100 mM sodium acetate pH 5.5, 1 mM EDTA, 3 
mM DTT, 2% DMSO, 30°C) for 30 minutes. Reaction was initiated by addition of 6 µg of 
collagen (Total reaction volume 26 µl). Reactions were quenched after 6 days by addition of 10 
µl of Laemmli’s SDS- Sample Buffer (4X, reducing) and heated to 95°C for 10 minutes. 20 µl of 
reaction mixtures were (3.3 µg of type I collagen) loaded to 4-15% gradient Bio-Rad Mini-
Protean® TGX
TM
 Gels. Gels were stained in Coomassie Brilliant Blue, G250 and imaging was 
performed using scanner. 
Cell culture: All the cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA). 
MDA-MB-231cells (American Type Culture Collection, Manassas, VA) were cultured on 10-cm 
plates (BD biosciences) at 37C and 5% CO2 in Iscove’s Modified Dulbecco’s medium with L-
glutamine (IMDM), 10% fetal bovine serum, and antibiotics (1% penicillin/streptomycin and 
0.5µg/ml fungizone) as described earlier 
106
. Cells were passaged at 1:3 ratio every 3–4
 
days and 
subcultured by 0.25% trypsin-EDTA treatment. Cells were re-plated one day prior to experiment 
so that the cell density was 80-90% on the day of the experiment.  
Confocal microscopy 
 For live-cell imaging, cells were trypsinized at ~ 80% confluency, seeded to Poly-D-
lysine coated 35mm-glass bottom dishes (MatTek; Ashland, MA) and grown overnight in 
complete medium, as described previously (Dana et al. 2013). Cells were treated with (0.05% 
Dimethyl-sulfoxide, DMSO) or Cathepsin-L inhibitor (750nM) inhibitors overnight, as 
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mentioned in the text. Prior to imaging, cells were treated with the substrate (Z-FR-AMC) for 2-
3 mins. 
  Images of live cells were acquired using an inverted Leica TCS-SP5 confocal 
microscope (Leica; IL) by Plan apochromat 63x1.4 oil objective lens. An argon ion laser (25%) 
was used to generate excitation at 488nm, and pinholes were typically set to 1–1.5 Airy units.  
Wound-healing cell migration assay:  For wound healing experiments, MDA-MB-231 cells were 
grown to confluence in a 6-well plate. Prior creating wound with a sterile pipette tip, the cells 
were treated with the vehicle control (0.05% Dimethyl-sulfoxide, DMSO) or Cathepsin-L 
inhibitor (750nM). Floating cells were removed by washing once with PBS. Images were 
captured by 4x objective at different time intervals. 
 Images were captured right after the scratch (‘wound’), t=0h, to record the initial area of 
the wounds, followed by image acquisition at t=22hrs to measure the recovery of the wounded 
area by cell migration under different conditions. The area of the ‘wound’ was quantified by 




. The migration of cells towards the 
denuded area (‘wound’) was expressed as a percentage of wound closure as: 
% of wound closure = [(At = 0 h – At = Δ h)/At = 0 h] × 100%, 
where At = 0 h is the area of the wound measured immediately after the scratch, and At = Δ h is the 




 Each experiment was performed a minimum of three times, and differences between 
groups were determined using the unpaired Student’s t test.  The data were evaluated as the mean 
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3.7 Transformation of Potent Specific Cathepsin L Inhibitor to Activity-Based 
      Probe 
 Functional roles of cysteine cathepsins in cancer cells often remain poorly understood. 
Although, many biochemical techniques including traditional genomic and proteomic have been 
utilized, often they provide the information only about the change in expression levels of the 
proteins. These parameters do not correlate with the cysteine cathepsins activity as they are 
expressed as inactive zymogens or exist in complex with their endogenous inhibitors.
157
 For 
example, a protease could be present in low abundance but may still be actively turning over its 
substrate. Because the activity of a protein is directly correlated to its function in vivo and given 
the fact that many proteins are post-translationally modified, an activity-based assessment of an 
enzyme is more directly relevant to its functional roles.
158
 Thus, the growing interest lies in 
correlating enzyme activity with its biological manifestation, such as oncogenic transformation 
or metastasis. 
 In this study, we seek to develop the first small molecule probe of cathepsin L that is 
highly sensitive, cell permeable, non-basic, and exquisitely selective. A photoaffinity-based 
cathepsin L probe has recently been reported.
157
 However, it suffers from severe limitations, 
which makes it totally incompatible for in vivo monitoring of cathepsin L activity in a natural 
cellular environment. These caveats mainly includes its (i) non-cell permeability that requires 
labelling experiments to be performed only after cell lysis, (ii) low affinity (Ki = 3.6 µM) and 
poor selectivity against analogous cathepsins (~only 3-6 fold against cathepsin S, K, and B). 
Thus, it is critically important to develop a small molecule cathepsin L inhibitor first which will 
covalently and irreversibly inactivate cathepsin L by targeting active site catalytic cysteine 
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residue. The inhibitory agent must also be selective, highly potent, stable, cell permeable, and 
non-basic in nature. We have developed a novel non-basic small molecule inhibitor of cathepsin 
L (KD-1) that is highly potent, selective and cell permeable. Careful investigation revealed that 
inclusion of an alkynyl moiety at 4-position of Cbz group will presumably retain the inhibitor 
activity towards cathepsin L while rendering it with a handle for a plausible copper-based click 
chemistry. The developed probe KDP-1 would find extensive usage in a variety of research 
applications, relevant to cathepsin-based anti-cancer drug development endeavors. These, for 
instances, may include (a) in situ tumor models for probing cathepsin L function, (b) validation 
of cathepsin L as a viable therapeutic target in individual cancer types, (c) assessment of in vivo 
pharmacodynamics property and efficacy of drug candidates, and (d) estimation of drug’s 
selectivity and off-target reactivity
137
, (e) investigating the importance of targeting cathepsin L 
alone in cancer cells that overexpress both cathepsin L and B; this is especially important given 
the fact these two share a common physiological protein substrate of extracellular matrix, a 
protein known to promote metastasis
43
 and (f) profiling the selectivity of cathepsin L-directed 




  Synthesis of KDP-1 was carried out according to scheme 3.2. Synthesis of P2 was 
achieved by treating 4-ethynyl benzylalcohol with triphosgene with sodium carbonate under 
anhydrous condition following a literature reported protocol.
160
 This was used for the next step 
without further purification. Chloroformate (P2) was dropwise added to a stirred slurry of  
methyl ester of phenyl alanine and sodium carbonate in water/toluene mixture to obtain 
intermediate P3.
161
 Ester hydrolysis was carried out by treating P3 with lithium hydroxide in 
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equimolar mixture of water and THF
162
. The free acid P4 thus obtained, was utilized in further 









3.9 Results and Experimental Propositions 
 The inhibitory efficacy of KDP-1 was evaluated against cathepsin L by following enzyme 
kinetics method. A, dose-dependent experiment was performed at various inhibitor 
concentrations and the progress curves were recorded under pseudo-first order conditions (i.e. 
[KDP-1]>>[Cat. L]). Analysis of the progress curves
58
 established KDP-1 as one of the most 
potent activity based probe known for cathepsin L (figure 3.5) (second order inactivation rate 







Scheme 3.2. Synthetic route adopted for the development of KDP-1. 
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Figure 3.8. [A] Time-dependent inhibition of human cathepsin L by KDP-1. Progress curves 
 for cathepsin L-catalyzed hydrolysis of fluorescent substrate, Z-Phe-Arg-(7-amino-4-
methylcoumarin), in the absence and presence of appropriate concentration of KDP-1. [B] 
Determination of second order inactivation rate constant (k
inact
) for KDP-1-mediated  
inhibition of human liver cathepsin L. The k
obs
 obtained from the progress curve fit were  
plotted against appropriate concentrations of KDP-1. The slope of the line yielded the  













 The effectiveness of KDP-1 to report the intracellular cathepsin L activity will be 
demonstrated in variety of carcinoma and normal cell lines. Detection of covalently modified 
cathepsin L will be accomplished using click chemistry approach. This technique offers an 
unique tag-less strategy to assess enzyme activity at proteome level in live cells.
163
 Click 
chemistry protocol allows formation of a triazole ring between two functional units (i.e. between 
acetylene and azide). Initially recombinant human liver cathepsin L will be incubated with KDP- 
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Incubate cell permeable cathepsin L probe, KDP-1,   
with metastatic and non-metastatic cancer cells  
1. Cell Lysis 
2. Detection using 
           Cu-Mediated  
           Click Chemistry  
 Highly Active  
Cathepsin L in 
Metastatic Cells 
Less active 
Cathepsin L in 
Non-Metastatic Cells 
Figure 3.9. The procedure involved in profiling intracellular cathepsin L 
activity in metastatic and non-metastatic cancer cells. 
1. KDP-1 will covalently and irreversibly modify cathepsin L via formation of a C-S bond with 
active site catalytic cysteine residue. The covalently modified enzyme will be subjected to 
aqueous friendly click chemistry protocol
164
 using rhodamine-azide. The rhodamide labelled 
protein will be serially diluted and the samples will be resolved using 10% SDS-PAGE. Labeled 
protein resolved on a denaturing gel will be visualized directly using Typhoon scanner (GE 
Healthcare). This will allow detecting minute quantity of active cathepsin L (as low as pmoles-
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fmoles). Once it is demonstrated in vitro; cell-based experiment will be carried out using MDA-
MB-231 cell lines. The process involves incubation of KDP-1 with MDA-MB-231 cells. Once 
the in vivo labelling is completed, the cells will be lysed and subjected to click chemistry 
followed by quantification of active enzyme by resolving it on SDS-PAGE (figure 3.6).  
3.10 Future Directions 
 The developed activity based probe KDP-1 could be further improved by changing the 
position of alkyne and amino acid substituents. Another latest strategy involving palladium-
mediated Suzuki-Miyuara coupling could be utilized for tag-less labelling experiments. In this 
strategy, no further modification on inhibitory scaffold will be needed. KD-1-mediated 
covalently modified enzyme could be subjected to a palladium catalyzed Suzuki-Miyuara cross 
coupling reaction with a fluorophore containing boronic acid under physiological conditions.
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3.11.1 Synthesis  
General.  
1
H NMR spectra were recorded at either 400 or 500 MHz using CDCl3 or DMSO 
as the solvent. 
13
C NMR spectra were recorded at either 125 or 100 MHz using CDCl3 or DMSO 
as the solvent. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to 
CDCl3 (7.26 ppm for 
1
H and 77.0 ppm for 
13
C), DMSO (2.50 ppm for 
1
H and 39.5 ppm for 
13
C). 
Coupling constants (J) are reported in Hertz (Hz) and multiplicities are abbreviated as singlet (s), 
doublet (d), doublet of doublets (dd), triplet (t), triplet of doublets (td), and multiplet (m). The 
mass spectra were acquired using a 6520 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) 
LC/MS (Agilent Technologies, Santa Clara, CA, USA). 4-ethynylbenzyl alcohol was purchased 
from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA).  O-(1H-6-Chlorobenzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased from peptide 
international (Louisville, Kentucky, USA). All anhydrous solvents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other materials were purchased from Fisher Scientific Inc. 
(Pittsburgh, PA, USA). 
Synthesis of Activity based probe KDP-1 
Synthesis of 4-ethynylbenzyl carbonochloridate (P2) 
 Synthesis of P2 was carried out using a literature reported protocol
160
. This was used for 
the next step without further purification. 
Synthesis of Methyl (((4-ethynylbenzyl)oxy)carbonyl)phenylalaninate (P3):  
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 Synthesis of this compound was carried out using a literature reported protocol
161
 and its 
characterization was found to be consistent with the previously reported NMR spectra.
162
  
Synthesis of (((4-ethylbenzyl)oxy)carbonyl)phenylalanine (P4) 
 Synthesis of this compound was carried out using a literature reported protocol and was 
used for the next step without further purification.
162
 
Synthesis of Ethyl (E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5-
methylhex-1-ene-1-sulfonate (P5) 
 To a stirred solution of the BOC-protected amine III (248 mg, 0.773 mmol) was added 
25% solution of trifluoroacetic acid in dichloromethane (5 ml) and stirred for 1 hr. The solution 
was removed in vacuo. The residue was dissolved in DMF(2 ml). To this was added a cocktail of 
P4 (250 mg, 0.773 mmol), HCTU (351mg, 0.85 mmol) and N,N-diisopropylethylamine (337μl, 
1.93 mmol) as a solution in anhydrous DMF (5 ml) at 0°C. Once the addition was done, ice bath 
was removed and the reaction was stirred overnight. The reaction was then diluted with 50 ml of 
ethyl acetate and washed with saturated ammonium chloride solution (25 ml), saturated sodium 
bicarbonate solution, and with brine (25 ml). The organic layer was dried over sodium sulfate 
and concentrated in vacuo.  Purification by flash column chromatography (silica gel; 80:20 
hexane/ethylacetate) provided 256 mg (yield: 63%) of product. Rf =0.25(70:30 
hexane/ethylacetate) 
1
H NMR (400 MHz CDCl3) δ ppm: 0.87 (m, 6H), 1.31 (m, 2H), 1.38 (t, J= 
7.0 Hz, 3H), 1.50 (M, 1H), 3.02 (dd, J= 13.5 Hz and 8.1 Hz, 1H), 3.09 (s, 1H), 4.14 (m, 2H), 
4.36 (m, 1H), 4.62 (m, 1H), 5.08 (m, 2H), 5.33 (bs, 1H), 5.75 (bs, 1H), 5.94 (d, J= 15.2 Hz, 1H), 
6.60 (dd, J=15.2 Hz and 5.1 Hz, 1H), 7.18 (d, J= 7.0Hz, 2H), 7.3 (m, 5H), 7.48 (d, J=8.2 Hz, 
2H). 
13
C NMR (100 MHz CDCl3) δ ppm: 14.90, 21.82, 22.65, 24.60, 38.27, 42.74, 48.03, 56.64, 
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66.75, 66.98, 77.76, 83.16, 122.19, 124.63, 127.58, 127.92, 129.07, 129.17, 132.36, 135.90, 
136.60, 147.59, 155.72,170.41. ). LRMS [ESI-MS +ve] calculated for (C28H34N2O6S +Na)
+
 : 
549.63, observed 549.78. 
Synthesis of 4-bromophenyl (E)-3-(2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-
phenylpropanamido)-5-methylhex-1-ene-sulfonate (KDP-1) 
 This compound was prepared using a literature reported protocol with appropriate 
modification. 
150
 To a stirred solution of P5 (300 mg, 0.57 mmol) in acetone was added tetrabutyl 
ammonium iodide (210.5 mg, 0.57 mmol) and refluxed for overnight. The mixture was 
concentrated in vacuo and was dissolved in anhydrous dichloromethane (4 ml). This was added 
to a stirred solution of triphenyl phosphine (299 mg, 1.14 mmol) and sulfuryl chloride (101.3 μl, 
1.254 mmol) in anhydrous dichloromethane (6 ml) at 0°C. Once the addition was done, ice bath 
was removed and the reaction was stirred overnight. The mixture was then concentrated in vacuo 
and passed through silica (oven dried) using hexane and ethyl acetate (90:10) to recover sulfonyl 
chloride as white solid. Subsequently, the sulfonyl chloride (260mg, 0.503 mmol) was dissolved 
in anhydrous dichloromethane (3 ml). 4-bromophenol (130 mg, 0.76 mmol) was added to the 
solution followed by addition of triethylamine (140 μl, 1.01 mmol) at 0°C. The mixture was 
stirred for one hr and diluted with ethyl acetate (30 ml) followed by washing with saturated 
ammonium chloride solution (15 ml), saturated sodium bicarbonate solution (15ml ×3), and with 
brine (15 ml). The organic layer was dried over sodium sulfate and concentrated in vacuo.  
Purification by flash column chromatography (silica gel; 90:10 hexane/ethylacetate) provided 
125 mg (after three steps yield: 40%) of the product as white solid. Rf = 0.52 (70:30 
hexane/ethylacetate). 
1
H NMR (400 MHz CDCl3) δ ppm: 0.82 (m, 6H), 1.22 (m, 2H), 1.41 (m, 
1H), 2.99 (dd, J= 13.5 and 8.4 Hz, 1H), 3.10 (dd, J= 13.5 and 8.4 Hz, 1H), 3.10 (s, 1H), 4.37 (m, 
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1H), 4.53 (m, 1H), 5.06 (m, 2H), 5.44 (bd, J=7.1 Hz, 1H), 5.89 (bd, J=5.2 Hz, 1H), 6.04 (d, 
J=15.1 Hz, 1H), 6.47 (dd, J= 15.1 and 5.3 Hz, 1H), 7.08 (m, 2H), 7.13 (m, 2H), 7.28 (m, 5H), 
7.49 (m, 4H) 
13
C NMR (100 MHz CDCl3) δ ppm: 21.85, 22.53, 24.57, 38.38, 42.34, 48.26, 
56.65, 66.75, 77.83, 83.16, 120.84, 122.20, 123.86, 124.45, 127.64, 127.88, 129.09, 129.15, 
132.36, 132.94, 135.86, 136.57, 148.36, 149.96, 155.93, 170.54 ). LRMS [ESI-MS +ve] 
calculated for (C32H33BrN2O6S +Na)
+
 : 676.57, observed 676.66. 
3.11.2 Enzyme Kinetics 
 Inhibitory efficacy of KDP-1 was assessed against cathepsin L by following the same 











Appendix A: NMR Spectra of Synthesized Arylsulfonyloxiranes. 
2-(4-Fluorophenyl)-3-(phenylsulfonyl)oxirane (1):  
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2-(Phenylsulfonyl)-3-propyloxirane (2):  
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2-(4-Chlorophenylsulfonyl)oxirane (3).  
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2-((4-Trifluoromethoxy)phenylsulfonyl)oxirane (4).  
 
1


















2-(2-Ethylphenylsulfonyl)oxirane (5).  
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2-(m-Tolylsulfonyl)oxirane (6).  
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2-(2,5-Dimethylphenylsulfonyl)oxirane (7):  
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2-(3-Methoxyphenylsulfonyl)oxirane (8):  
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2-(2,5-Dimethoxyphenylsulfonyl)oxirane (9):   
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(j) 2-(Naphthalen-3-ylsulfonyl)oxirane (11):  
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H COSY spectrum of 2. Observed crosspeaks establish the connectivity between 








H heteronuclear COSY spectrum of 2. Observed crosspeaks establish the 
assignment of protons and the carbons directly attached to it. C3 and H3 are not shown in the 








C HMBC spectrum of 2. Peaks marked A to G are assigned as follows. A: Hc-Ca B: 





connectivity illustrated through peaks A to G help establish the assignment of quaternary carbons 
a and a’ as well as distinguish the two rings. Olefinic proton 2 and aliphatic proton 3 and show 
three bond coupling to Ca’ and Cb’ respectively which clearly establishes the position of double 













































































H COSY spectrum of 9. Observed crosspeaks establish the connectivity between 








C heteronuclear HSQC spectrum of 9. Observed crosspeaks establish the 
assignment of protons and the carbons directly attached to it. H1 and C1 are not shown in the 








C HMBC spectrum of 9. Peaks marked A to E are assigned as follows. A: Hc-Ca B: 




C connectivity illustrated 
through peaks A to E help establish the assignment of quaternary carbons a and a’ as well as 
distinguish the two rings. Olefinic protons 2 and 3 show three bond coupling to Ca’ and Cb’ 


























































C NMR spectrum of 15. 
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C NMR spectrum of 16E and 16Z.  
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H  COSY spectrum of the mixture of 16E and 16Z 
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C crosspeaks for both compounds are illustrated in the figure. 
 









                                          











    
 
 





H  COSY spectrum of the mixture of 19E and 19Z 








                                         
               
 
 
























X-ray Structure Determination of Compound 2 
A clear fragment of 2 with approximate dimensions 0.18 mm x 0.40 mm x 0.51 mm, cut from a 
cluster of crystals obtained by crystallization at room temperature from ethyl acetate/hexanes, 
was used for the X-ray crystallographic analysis. The X-ray intensity data were measured on a 
Bruker Smart Breeze CCD system equipped with a graphite monochromator at 100(2) K, cooled 
by an Oxford Cryosystems 700 Series Cryostream. A total of 1464 frames were collected. The 
total exposure time was 4.07 hours.  The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. The integration of the data using a monoclinic 
unit cell yielded a total of 7242 reflections to a maximum θ angle of 27.26° (0.78 Å resolution), 
of which 2900 were independent (average redundancy 2.497, completeness = 99.8%, Rint = 
2.07%, Rsig = 2.62%) and 2850 (98.28%) were greater than 2σ(F2). The final cell constants of a 
= 5.6179(5) Å, b = 7.6160(6) Å, c = 15.3045(13) Å, β = 95.8260(10)°, volume = 651.43(10) Å
3
, 
are based upon the refinement of the XYZ-centroids of 4601 reflections above 20 σ(I) with 
5.349° < 2θ < 54.435°. Data were corrected for absorption effects using the numerical method 
(SADABS). The ratio of minimum to maximum apparent transmission was 0.915. The calculated 
minimum and maximum transmission coefficients (based on crystal size) are 0.8883 and 0.9583.  
 The structure was solved and refined using the Bruker SHELXTL Software Package, 
using the space group Pn, with Z = 2 for the formula unit, C15H14O2S. The final anisotropic full-
matrix least-squares refinement on F2 with 163 variables converged at R1 = 2.80%, for the 
observed data and wR2 = 7.00% for all data. The goodness-of-fit was 1.065. The largest peak in 
the final difference electron density synthesis was 0.231 e¯/Å
3
 and the largest hole was -0.179 
e¯/Å
3
 with an RMS deviation of 0.040 e¯/Å
3
. On the basis of the final model, the calculated 
density was 1.317 g/cm
3
 and F(000), 272 e¯.  
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 Cambridge Crystallographic Data Centre deposition number for 2: CCDC 916842. The 





Figure S28.  ORTEP
1
 drawing of 2 with complete numbering of atoms, viewed approximately 
normal to the alkene plane.  Selected bond lengths (Å) and angles (°):  S1-O1, 1.443(1); S1-O2, 
1.443(1); S1-C1, 1.753(2); S1-C4, 1.760(2); C1-C2, 1.320(2); C2-C3, 1.504(2); C3-C10, 
1.525(2)O1-S1-O2, 118.37(8); O1-S1-C1, 109.14(7); O2-S1-C1, 107.07(8); O1-S1-C4, 
108.38(7); O2-S1-C4, 108.07(7), C1-S1-C4, 105.01(7); C2-C1-S1, 120.9(1); C1-C2-C3, 
124.6(2); C2-C3-C10, 110.3(1). 
1




Appendix C: NMR Spectra of Synthesized Vinyl Sulfonates 
4-Bromophenyl ethenesulfonate (1): 














Quinolin-8-yl ethenesulfonate (2): 













5-Nitroquinolin-8-yl ethenesulfonate (3): 








C NMR spectrum of 3. 
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[1,1’-Biphenyl]-4-yl ethenesulfonate (4): 












4’-Nitro-[1, 1’-biphenyl]-4-yl ethenesulfonate (5): 












Methyl 2-((vinylsulfonyl) oxy) benzoate (6): 












Methyl 4-((vinylsulfonyl) oxy) benzoate (7): 












4-Cyanophenyl ethenesulfonate (8): 











4-Nitrophenyl ethenesulfonate (9): 












5-Fluoro-2-nitrophenyl ethenesulfonate (10): 













4-Chlorophenyl ethenesulfonate (11): 














C NMR spectrum of 11 
 
2-Chlorophenyl ethenesulfonate (12): 








C NMR spectrum of 12. 
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3-Chlorophenyl ethenesulfonate (13): 














4-Chloro-2-fluorophenyl ethenesulfonate (14): 













4-Chloro-3-fluorophenyl ethenesulfoante (15): 














4-Chloro-3-(trifluoromethyl) phenyl ethenesulfonate (16): 












4-Chloro-2, 3, 5, 6-tetrafluorophenyl ethenesulfonate (17): 











4-Chloro-3-methylphenyl ethenesulfonate (18): 













4-Chloro-3, 5-dimethylphenyl ethenesulfonate (19): 












4-Chloro-2-nitrophenyl sulfonate (20): 







C NMR spectrum of 20. 
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3, 4-Dichlorophenyl ethenesulfonate (21): 















2, 4, 5- Trichlorophenyl ethenesulfonate (22): 













2, 4, 6-Trichlorophenyl ethenesulfonate (23): 













Methyl 5-chloro-2-((vinylsulfonyl) oxy) benzoate (24): 












4-Fluorophenyl ethenesulfonate (25): 













4-Iodophenyl ethenesulfonate (26): 













2-Ethylphenyl ethenesulfonate (27): 
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